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Abstract 
Information and Communication Technology (ICT) tools can efficiently support clinical 
research by providing means to collect automatically huge amount of data useful for the 
management of clinical trials conduction. Clinical trials are indispensable tools for 
Evidence-Based Medicine and represent the most prevalent clinical research activity. 
Clinical trials cover only a restricted part of the population that respond to particular and 
strictly controlled requirements, offering a partial view of the overall patients’ status. For 
instance, it is not feasible to consider patients with comorbidities employing only one kind 
of clinical trial. Instead, a system that have a comprehensive access to all the clinical data 
of a patient would have a global view of all the variables involved, reflecting real-world 
patients’ experience. The Learning Health System is a system with a broader vision, in 
which data from various sources are assembled, analyzed by various means and then 
interpreted. The Institute of Medicine (IOM) provides this definition: “In a Learning Health 
System, progress in science, informatics, and care culture align to generate new knowledge 
as an ongoing, natural by-product of the care experience, and seamlessly refine and deliver 
best practices for continuous improvement in health and health care”.  
The final goal of my project is the realization of a platform inspired by the idea of Learning 
Health System, which will be able to re-use data of different nature coming from 
widespread health facilities, providing systematic means to learn from clinicians’ 
experience to improve both the efficiency and the quality of healthcare delivery. 
The first approach is the development of a SOA-based architecture to enable data collection 
from sparse facilities into a single repository, to allow medical institutions to share 
information without an increase in costs and without the direct involvement of users. 
Through this architecture, every single institution would potentially be able to participate 
and contribute to the realization of a Learning Health System, that can be seen as a closed 
cycle constituted by a sequential process of transforming patient-care data into knowledge 
and then applying this knowledge to clinical practice. Knowledge, that can be inferred by 
re-using the collected data to perform multi-site, practice-based clinical trials, could be 
concretely applied to clinical practice through Clinical Decision Support Systems (CDSS), 
which are instruments that aim to help physicians in making more informed decisions. With 
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this objective, the platform developed not only supports clinical trials execution, but also 
enables data sharing with external research databases to participate in wider clinical trials 
also at a national level without effort. The results of these studies, integrated with existing 
guidelines, can be seen as the knowledge base of a decision support system. 
Once designed and developed, the adoption of this system for chronical infective diseases 
management at a regional level helped in unifying data all over the Ligurian territory and 
actively monitor the situation of specific diseases (like HIV, HCV and HBV) for which the 
concept of retention in care assumes great importance. The use of dedicated standards is 
essential to grant the necessary level of interoperability among the structures involved and 
to allow future extensions to other fields. 
A sample scenario was created to support antiretroviral drugs prescription in the Ligurian 
HIV Network setting. It was thoroughly tested by physicians and its positive impact on 
clinical care was measured in terms of improvements in patients’ quality of life, 
prescription appropriateness and therapy adherence. The benefits expected from the 
employment of the system developed were verified. Student’s T test was used to establish 
if significant differences were registered between data collected before and after the 
introduction of the system developed. The results were really acceptable with the minimum 
p value in the order of 10−5 and the maximum in the order of 10−3. It is reasonable to 
assess that the improvements registered in the three analysis considered are ascribable to 
this system introduction and not to other factors, because no significant differences were 
found in the period before its release. 
Speed is a focal point in a system that provides decision support and it is highly recognized 
the importance of velocity optimization. Therefore, timings were monitored to evaluate the 
responsiveness of the system developed. Extremely acceptable results were obtained, with 
the waiting times of the order of 10−1  seconds. 
The importance of the network developed has been widely recognized by the medical staff 
involved, as it is also assessed by a questionnaire they compiled to evaluate their level of 
satisfaction.  
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1 Introduction 
1.1 Context 
In the last years, worldwide National Health Institutes are becoming always more aware of 
the importance of ICT in healthcare [1]. Consequentially, the government of many 
countries have planned remarkable investments in the implementation of ICT solutions in 
the healthcare setting [2]. In particular, Italy is doing significant efforts to develop a 
federated Electronic Health Record (EHR) called Fascicolo Sanitario Elettronico (FSE). 
The EHR is a computer-based record of patients’ health information that includes 
information about patients’ demographics, medications, vital signs, clinical history, 
immunizations, laboratory results, and reports of diagnostic procedures [3]. On September 
3rd 2015 the Italian Minister of Health Lorenzin has signed the national directives and 
guidelines for FSE. According to these directives, the Regions have to set up the 
implementation of the infrastructures needed to guarantee the correct level of 
interoperability for FSE. The subsequent amendments introduced to Legislative Decree n. 
179/2012 with the Legislative Decree of June 21st 2013, n. 69, entitled "Urgent Provisions 
for the Recovery of the Economy" (converted, with amendments, from the Law of August 
9th 2013, No.98), established the deadline for the activation of the FSE at the Regions and 
Autonomous Provinces on June 30th 2015. The most recent Legislative Decree of August 
4th 2017 defines the technical modalities and the telematics services made available by the 
national infrastructure for the interoperability of the FSE [4]. 
Despite the deadline, most regions are presently developing the infrastructure to support 
FSE (November 2017), and in the last two years, only few regions already provide citizens 
with a complete and operating FSE, as reported in figure 1.1 and 1.2. 
9 
 
 
Figure 1.1: Indicator of the percentage of citizens that have access to their personal FSE, distributed per 
regions. Statistics from the official Italian FSE web site, last update November 2017. 
 
Figure 1.2: Data about the territorial distribution of infrastructures supporting FSE and the related adoption 
by citizens. 16 regions have adopted infrastructures to support FSE, but only 11 can support 
interoperability. About 11 thousand FSE were activated by citizens corresponding to about 30 thousand of 
digital reports created. Statistics from the official Italian FSE web site, last update November 2017. 
The Legislative Decree of October 18th 2012 n.179 converted with amendments by Law 
December 7th 2012 n. 221 on "Further Urgent Measures for Growth of the Country" states 
in Article 12 the legal provision prepared by the Ministry of Health, which governs the FSE 
at national level. In particular, paragraph 2 of that article states that it is set up by the 
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Regions and Autonomous Provinces, not only for clinical care purposes but also for 
scientific research purposes. Systematic research mainly consists in clinical trials, which 
are essential tools for the conduction of focused surveys. Clinical trials give a partial vision 
of patients’ status, since the population considered is a restricted part that respond to 
particular and strictly controlled requirements. For these reason, it is not feasible to 
consider patients with comorbidities employing only one kind of clinical trials. A system 
that have a comprehensive access to all the clinical data of a patient would have a global 
view of all the variables involved, reflecting real-world patients’ experience.  
Federated FSE should be based on medical standards to grant interoperability among 
different Regions, in order to share data at a national level. The Ministry of Health suggest 
the use of Health Level 7 (HL7) Clinical Document Architecture Release 2 (CDA r2). 
Liguria region does not supply complete FSE functionalities yet. Nevertheless, physicians 
have expressed their need to employ a computerized infrastructure that supports data 
collection from different healthcare institutions of the territory to enable the conduction of 
multicenter clinical trials. 
1.2 Objectives 
The main issue addressed by this thesis is the lack of interoperability between different 
healthcare institutions at intra-regional level, resulting in communication problems and 
difficulties in data exchange. Fixing that problem, would allow the creation of a common 
framework for data sharing that, similarly to the described FSE, can support data re-use for 
research purposes. 
In this view, the final goal of my project is the realization of a platform inspired by the idea 
of Learning Health System [5], applied to the chronic infectious disease field. The LHS 
can be seen as a closed cycle constituted by a sequential process of transforming patient-
care data into knowledge and then applying this knowledge to clinical practice. A concrete 
application of this concept would involve a standardized framework that allows clinical 
data collection from widespread health facilities, creating a common data base suitable for 
data re-use. In this vision, data from everyday clinical care are available for clinical studies, 
thus enabling integration between clinical care and medical research worlds. Within this 
relationship, systematic means to learn from clinicians’ experience can improve both the 
efficiency and the quality of the healthcare delivery. 
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The first step for the implementation of such a system is the development of a SOA-based 
architecture to enable data collection from sparse facilities into a single repository, to allow 
medical institutions to share information without an increase in costs and without the direct 
involvement of users. Through this architecture, every single institution would potentially 
be able to participate and contribute to the realization of a Learning Health System. 
Knowledge, that can be inferred by re-using the collected data to perform multi-site, 
practice-based clinical trials, could be concretely applied to clinical practice through 
Clinical Decision Support Systems (CDSS), which are instruments that aim to help 
physicians in making more informed decisions. With this objective, the second step of the 
development of my project was the realization of a platform that not only supports clinical 
trials execution, but also enables data sharing with external research databases to participate 
in wider clinical trials also at a national level without effort. The results of these studies, 
integrated with existent guidelines, can be seen as the knowledge base of a decision support 
system, which development consisted in the third step of the project. Once designed and 
developed, the adoption of this system for chronical infective diseases management at a 
regional level helped in unifying data all over the Ligurian territory and actively monitor 
the situation of specific diseases (like HIV, HCV and HBV) for which the concept of 
retention in care assumes great importance [6]. 
The use of dedicated standards is essential to grant the necessary level of interoperability 
among the structures involved and to allow future extensions to other fields and 
participants. 
1.2.1 Learning Health System 
The Institute of Medicine (IOM) provides this definition: “In a Learning Health System, 
progress in science, informatics, and care culture align to generate new knowledge as an 
ongoing, natural by-product of the care experience, and seamlessly refine and deliver best 
practices for continuous improvement in health and health care” [7]. 
This emerging idea was born in the USA and developed until now importing successful 
experiences coming from other sectors. It aims at the formation of a knowledge starting 
from data that can be shared through ICT tools, with the purpose of re-evaluate and improve 
processes and activities, thus ensuring a greater effectiveness of care when applied in the 
healthcare context [8]. 
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In Europe even if the efficacy of this vision is widely recognized [9], there are only 
scattered islands of innovation ready to constitute an initial core of an European learning 
health system, but at a central policy level, its adoption as an organizational approach is 
not considered one of the imminent goals. The main cause of this organization delay is due 
to European history in which language and cultural differences are extremely relevant. This 
reasons result also in technical differences like clinical formats and units of measure that 
make the automatic sharing of data contained within Electronic Patient Record (EPR) 
extremely difficult. The use of standards at any level of the sharing process would 
significantly improve the feasibility of this operation [10]. 
The use of ICT (Information and Communication Technology) tools (e.g. electronic record 
systems, data transmission infrastructures and clinical networks) represents one of the 
prerequisites for the development of a learning health system, whose main goal is to adopt 
structured knowledge in order to improve activity and processes in medical field [10]. 
In LHS, the strong integration between medical research and patient-care practice is a key 
concept. 
The learning health system can be seen as a closed cycle constituted by a sequential process 
of transforming patient-care data into knowledge and then applying this knowledge to 
clinical practice. In my project, this kind of knowledge is meant to be concretely applied to 
clinical practice through a Clinical Decision Support System, which is an instrument that 
aims to help physicians in making more informed decisions. Different types of CDSS exist, 
basing on the different ways of inferring knowledge from patient’s specific data: rule-based 
CDSS or inferential CDSS [11]. A rule-based CDSS rest on the knowledge that could be 
extracted from existent clinical guidelines combined with the inferences from the results of 
experimental research and clinical trials performance [12].  
The flux diagram in figure 1.3 shows the cycle of LHS. The CDSS is integrated into the 
care environment to provide support in care practice, based on real time patients data 
coming from the computer based patient’s record. The experimental research conducted 
through practice-based research networks provides knowledge that is published in the 
literature. This knowledge combined with those coming from guidelines forms the 
knowledge base of the CDSS. 
13 
 
 
Figure 1.3: Diagram showing the cycle of LHS. Data from guidelines and literature are translated and 
synthesized into knowledge that is incorporated into the Clinical Decision Support System and in parallel 
disseminated to stakeholders. The care environment benefits from these tools. Data from clinical practice 
are collected through computer-based patient record and re-used for experimental research, serving as base 
for new publications, thus closing the cycle. 
In a health system that “learns” every consenting patient’s characteristic and experiences 
are, in principle, available for study and best practice knowledge is immediately available 
to support decisions. Improvement is continuous through ongoing studies while learning 
happens routinely, economically and almost invisibly. 
1.3 State of the art of Learning Health System 
In the United States, Friedman et al laid the foundations to the vision of the Learning Health 
System, which main goal is to adopt structured knowledge in order to improve activity and 
processes in the medical field [8]. Since its first definition in 2007, the LHS has evolved 
from an intriguing idea to a nascent reality. In the United States in the last few years, many 
networks of institutions that aim at achieving the principal LHS capabilities aroused. In 
2014, the Patient Centered Outcomes Research Institute (PCORI) invested more than $250 
million in the development of the National Patient-Centered Clinical Research Network 
(PCORnet), which is a “network of networks” that collects data routinely gathered in a 
14 
 
variety of healthcare settings all spread among the US [13]. The aim is the re-use of these 
data, in order to enable people to make informed healthcare decisions by efficiently 
conducting clinical research relevant to their needs. PCORnet includes 13 Clinical Data 
Research Networks, 20 People-Powered Research Networks, and 2 Health Plan Research 
Networks. Among these, two important PCORI funded LHS projects that are still in 
development are the “Patient-Centered Network of Learning Health Systems” (LHSNet) 
in Minnesota [14] and the “Pediatric Learning Health System” (PEDSnet) in Pennsylvania 
[15], both started in 2015 with an expected duration of three years.  
The Scalable Collaborative Infrastructure for a Learning Health System (SCILHS) is a 
Clinical Data Research Network that participates in the PCORnet. SCILHS includes 12 
health centers across the United States that use i2b2 (Informatics for Integrating Biology 
and the Bedside) software to collect and analyze patient data for clinical research. I2b2 is 
a data warehouse funded by the National Institute of Health (NIH) to re-use clinical data 
for research purposes [16]. This system allows the exchange of information between clinic 
and research fields, facilitating the testing of research results through clinical trials and 
using data generated by clinical practice for research purposes. The i2b2 software consists 
of a collection of independent modules called “cells” that constitute the so-called “hive”. 
Each cell interact with the others using web services and XML messages.  
An important LHS project already developed that focuses on the study of a single disease 
is Cancer Learning Intelligence Network for Quality (CancerLinQ), a LHS in oncology 
designed by the American Society of Clinical Oncology (ASCO) [17] [18]. It was formally 
launched in 2015 and presently it has more than one million patient records in the system 
from the main US states. 
These are examples of working Learning Health System projects. There are also diffuse 
architectures that support clinical data sharing across different institutions, above which a 
Learning Health System could be built. In 2008 Harvard started a project with the aim to 
enable collaboration across the Harvard schools and affiliated hospitals and institutions 
[19]. The main issue was sharing patient data using a federated model where each 
institution  would maintain control over their local databases. I2b2 software was used at 
each site. Shared Health Research Information Network (SHRINE) was built to link their 
respective i2b2 instances for the sharing of data [19]. SHRINE is currently in play at other 
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sites in USA such as i2b2-CICTR (Cross-Institutional Clinical Translational Research 
project) [16] and CARRAnet (Childhood Arthritis and Rhematological Research Alliance) 
[20]. 
A proof-of-concept architecture for a network-based LHS has also been realized in the 
chronic diseases field, with the aim of predicting models from data collected through which 
deliver the best possible treatments [21]. In this paper, Marsolo et al. assert that knowledge 
generated by the huge amount of data coming from chronic patients can be applied in 
routinely patient care through decision support systems. The use of standards at any level 
of the sharing process significantly improves the feasibility of such a system. In their work, 
Marsolo et al. propose the introduction of standards as a future development, and in 
particular, they suggest the use of Health eDecisions (HeD) standards. The Health 
eDecisions (HeD) initiative, supported by HL7 (Health Level 7) International and OMG 
(Object Management Group). ) is an initiative of the Office of the National Coordinator‘s 
Standards & Interoperability Framework [22][23]. HeD does not aim to create a new 
standard, but its intent is to identify, define and harmonize already existing standards 
involved in clinical decision support field. 
While in the US during the last few years the concept of LHS was increasingly 
consolidated, in the rest of the world there are only scattered islands of innovation ready to 
constitute an initial core of a Learning Health System, even if the efficacy of this vision is 
widely recognized [24]. In the last years, some projects about repurposing clinical data 
collected in the Electronic Healthcare Record (EHR) for use in clinical research are 
diffusing in Europe. EHR4CR (Electronic Health Records for Clinical Research), is an 
European project funded by Innovative Medicines Initiative (IMI) and the European 
Federation of Pharmaceutical Industries and Associations (EFPIA) which aims to provide 
adaptable/reusable and scalable solutions for reusing EHR data for clinical research [25]. 
It involves 34 academic and private partners and 11 hospital sites in France, Germany, 
Poland, Switzerland and the United Kingdom. The EHR4CR platform supports distributed 
querying to assist in clinical trials feasibility assessment and patient recruitment. Software 
connectors offer the possibility to use the EHR4CR reference implementation with an i2b2 
clinical data warehouse [25]. 
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In Europe the only example of LHS reported in literature is the TRANSFoRm project, an 
EU funded large scale project, which aims to develop and evaluate a LHS for European 
Primary Care [26] [27]. TRANSFoRm project has three main areas of application: 
facilitation of multiple site genotype-phenotype studies, enabling multi-site practice-based 
clinical trials and improvement of diagnosis by provision of a diagnostic decision support 
system linked to Electronic Health Records (EHR). In this project CDISC (Clinical Data 
Interchange Standards Consortium) SDM (Study Design Model) standard was adopted for 
study design. TRANSFoRm project involves 10 European countries, but Italy is not 
included. Italy is doing significant efforts to develop a federated Electronic Health Record 
(EHR) called Fascicolo Sanitario Elettronico (FSE). With this tool, Italian regions have to 
set up infrastructures that guarantees interoperability and data sharing at inter-regional 
level. Actually, such a comprehensive system has not been already achieved since data 
cannot be shared in a standardized way between regions because each of them has its own 
architecture. The concept of learning health system needs to be eradicated into a fully 
linked system to be significant. The development of this project could be the starting point 
for such approach, especially because its standardized and innovative solution can easily 
open the system to other regions. 
The learning health system is a closed cycle in which medical knowledge is extracted from 
patient-care data and then it is applied to clinical practice. In my project, this kind of 
knowledge is meant to be concretely applied to clinical practice through Clinical Decision 
Support Systems (CDSS). 
The importance of decision support systems is highly acknowledged as a key strategy to 
improve medical safety and quality of care [28]. In the past, cultural and technological 
barriers have prevented a broad application of CDSS across the healthcare setting. The 
evolution in the adoption of health IT during the years, together with the resulting increase 
of availability of digital data from Electronic Health Records (EHR) have played an 
important role in the evolution and adoption of CDSS [29]. Different kind of CDSS exist: 
guideline-based clinical decision support systems can offer to physicians patient-specific 
advices based on guideline recommendations. In the literature a great number of CDSS 
implementations are described for different medical fields [30] [31] [32] [33] [34]. 
Specifically, there are CDSS implementations also in HIV field, which have the potential 
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to improve specialty medical care by monitoring laboratory results and patients follow-up 
[35]. 
Most studies on the efficacy of the current CDSS implementations reveal that only the 
process outcomes benefit from these systems, while little improvements are registered in 
clinical outcomes [30] [32] [36]. To improve clinical outcomes, the automated decision 
support should be strictly interconnected with the process of care. Among the great number 
of computerized CDSS arousing in every medical field, a recent review shows that only 
few CDSSs delivered their recommendations at the point of care [37]. Therefore, these 
stand-alone systems need to be integrated into clinical practice. This should be done 
through the implementation of a Learning Health System, that applies the knowledge 
generated from the patient-care data to clinical practice through Clinical Decision Support 
Systems (CDSS).  
A strong interoperability between the hospital EHR and the CDSS is the key to reach a 
most reliable decision support, that could aid in better diagnosis, reduce medication errors 
and improve practitioner performances [29]. A problem that arouses in the coupling of 
EHR and CDSS is the heterogeneity of clinical data sources and, as asserted by Kawamoto 
in 2010, the lack of a common information model and standardized clinical terminology 
force CDSS interfaces to have custom mappings between systems [38]. Different kind of 
standards are needed for data mapping and representation, for knowledge representation, 
re-use and transfer and for system intercommunication [39]. According to a review 
published in 2016, only 22% of the systems considered use standards for guidelines 
representation, 63% use clinical information standards, 46% outline the use of standard 
terminologies, and 32% report the use of web services to offer CDS functionalities [40]. 
Healthcare standards such as OpenEHR, ISO 13606-1:2008 and HL7 standards are used to 
enhance the communication between EHRs and clinical applications or middleware 
components [41]. The knowledge base of the decision support system in LHS is a 
combination of the evidence coming from clinical trials and clinical guidelines. Many 
standards are available to represent clinical guidelines in computable format, with the aim 
to simplify updating and sharing [41]. 
In accordance with the CDSS implementation needs, there is a great variety of standards 
that can facilitate implementation, but each of them has different gaps and challenges. In 
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their review, Kawamoto et al recommend that efforts should be made to harmonize and 
recommend the use of existing standards [39]. Health eDecision is such an initiative which 
intent is to identify, define and harmonize already existing standards involved in clinical 
decision support field [23]. During the very last years the first implementations of CDSS 
relying on the standards defined by the HeD initiative are rising. Besides the pilot study 
[42] and its applications [43], Zhang et al developed an infrastructure that is entirely based 
on these standards [44], assessing that, compared with other CDSS systems, their approach 
improves system maintainability, scalability and efficiency and saves time and cost in 
system development and implementation. 
Speed is a focal point in a system that provides decision support and it is highly recognized 
the importance of velocity optimization [45].  
  
19 
 
2 Materials 
2.1 Existing scenario 
In 2011 the regional research network called Ligurian HIV Network (LHN) was 
implemented by some colleagues in Medinfo laboratory [46] [47]. The LHN was originally 
conceived as a mere web platform to enable the collection of data from HIV patients using 
a web interface, in order to perform multi-centric clinical trials at a regional level. The 
system relies on a relational database, which has a high data structuring through a meta-
description approach, which permits the archiving of various types of clinical information. 
The web platform was developed in Microsoft VB .NET and visualization is standardized 
through the use of Microsoft .ascx templates, through which the web pages are loaded 
dynamically based on a specific tables structure. 
The instrument developed provides a complete clinical vision of patients, granting data 
integration between the different types of clinical studies hosted on the platform and 
granting flexibility in data extraction through specific instruments that allow user 
customization. 
For the first years, the platform was consistently used for its initial scope, supporting about 
half a dozen local studies. Routine use of the platform, together with the intention to address 
the well-known problem of errors due to manual data input into web interfaces, led to a 
consecutive gradual evolution of the system. The leading idea was that clinical data, already 
available in digital format in the LIS (Laboratory Information System) and other 
components of the Hospital Information System (HIS), could be extracted and 
automatically exported to the LHN database. In this way, patients’ laboratory data could 
be updated daily without human intervention. In the previous works on the first prototype 
of LHN, the lack of integration between medical informatics and clinical research was 
pointed as one of the main critical point to be addressed. 
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2.2 Hospital EHRs network 
The leading idea was to connect the main hospitals involved in the LHN in order to create 
a network to share information about patients. This network should allow the management 
of patients in a comprehensive way, granting the ability to track their clinical path in the 
regional territory. The EHR of each hospital has to be connected to the LHN database and 
a program has to organize data updating without human intervention. 
The idea was submitted to the judgment of the Ligurian Ethics Committee that approved 
the proposed architecture and its functionalities. 
Three hospitals agreed to connect to the network and provided access to their Hospital 
Information System. The three hospitals are Ospedale Policlinico San Martino of Genova, 
Ospedali Galliera of Genova and Ospedale di Sanremo of Sanremo (IM). Each hospital has 
a different informative system, so two different ways to make data accessible have been 
developed. Galliera offers several services to access patients' clinical data, including a data 
management service to access laboratory exams results. After authentication, data are 
available on demand in XML or JSON format. Data can be queried by the patient 
identification code and can be furtherly filtered using the date of the exam. Contrariwise, 
San Martino and Sanremo do not have services so the only way to access data is to directly 
extract them from the Electronic Health Record (EHR). A VPN connection is necessary to 
reach the hospital server, while an ODBC connection has to be used to achieve its database. 
San Martino and Sanremo hospitals created a custom account providing read-only access 
to some views. One of the views supplies administrative data, while the others allow access 
to clinical data, in particular those coming from laboratory tests, microbiological tests and 
antibiotic resistance tests.  
In all cases, only a restricted part of the hospital information system is accessible, and 
sensitive patients’ data are not visible, according to privacy issues. The management of 
patients’ identity will be done in a pseudo-anonymous way through hospital identification 
codes. When a patient is registered into a hospital for the first time, he is given an 
alphanumeric identification code and every action related to the patient will be registered 
associated to this ID. The association between the patient’s identity and the identification 
code is registered only in the hospital’s demographic and cannot be accessed from outside. 
Each hospital associates a different identification code for the same patient. 
21 
 
The main clinical information that was made available by the three hospitals concerns 
laboratory tests, microbiological tests, therapies, serology and resistance patterns. Each 
hospital uses its own terminology and no standard vocabularies are employed in their 
systems. Thus, the hospital HIS administrators provided a complete schema of all the 
exams supported, mapped with local codes and descriptions. 
The immunization administered to patients involved in the LHN with the related 
information of injection date, typology and dose are of interest too. Immunization data are 
not stored into hospital databases: there is a unique computerized immunization registry 
that manages immunization data storage in the Genoa metropolitan area and province. The 
company responsible of the administration of this system developed a web service to 
provide access to its content through standard CVX codes. 
2.3 Clinical trials in chronical infectious diseases 
Evidence Based Medicine (EBM) is the process of research, evaluation and systematic use 
of the results of contemporary research as a basis for clinical practice. Clinical trials are 
indispensable tools for Evidence-Based Medicine [48]. They are used in many clinical 
areas to evaluate the effectiveness of a specific protocol of treatment or drug therapy in a 
group of patients in order to be able to infer the possible treatment. There are different types 
and stages of clinical trials but all share similar characteristics [49]. The main classification 
consists in observational and interventional trials. During observational studies, the 
researchers simply observe the patients and register the outcomes. In interventional studies, 
the researchers administer the drug under study or other kind of intervention and compare 
the outcomes with those of non-treated patients. Observational studies divide into two sub-
categories: cohort studies and case-control studies. In cohort studies, a population is 
observed in a certain period of time to detect potential risk factors or other communal 
characteristics. This inspection can be carried on considering only past data or collecting 
oncoming data. The first one is called retrospective study, the second one is called 
prospective study. Case-control studies compare a group of subjects with a particular 
disease with a group of healthy subjects to evaluate the exposure to certain risk factors. 
Pre-clinical studies in vitro or in vivo on animals generally precede interventional studies. 
Interventional studies are in vivo tests on human that pass through different phases. Usually 
they start from phase 0, which consists in pharmacodynamics and pharmacokinetics 
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evaluation in human. Phase 1 is a screening for safety and allows evaluating the quantity 
of drug that is administrable to a restricted sample of subjects without registering serious 
adverse events. Phase 2 establishes the efficacy of the treatment administered to a bigger 
sample of subjects (usually 20-300 subjects). Case-control studies could be conducted in 
parallel to evaluate the treatment effects. Phase 3 provides a general evaluation on a bigger 
sample of subjects (usually 300-3000 subjects). After phase 3, the treatment can be 
commercialized. Phase 4 is a post marketing surveillance phase, called pharmacovigilance. 
The results of the research will be much better as the quality of the data collected and 
analyzed is accurate. Data management is a critical point during the planning of a trial 
steps. Clinical trials may involve only one specialist center or group of centers. In the latter 
case, a larger amount of data will be collected and it will be easier to generalize samples as 
a global population rather than a single center. Information technology can facilitate 
clinical trials conduction in different phases such as data entry, database deployment and 
management, statistical and inferential processing, and data transfer. 
In multicentric clinical trials, use of Clinical Data Management Systems (CDMS), such as 
the LHN, has become essential to handle a huge amount of data. The LHN web platform 
coordinates the conduction of different regional clinical trials in HIV field based on the 
amounts of data collected from the hospitals involved. Different types of clinical trials are 
managed on the LHN: those focused primarily on clinical aspects and therapy, which is a 
key trait for HIV patients and those focused on managerial and economical aspects [47]. 
At a national level, there are different databases that collect data from different institutions 
on the national territory to perform wider clinical trials. The ARCA (Antiretroviral 
Resistance Cohort Analysis) [50], ICONA (Italian COhort Naïve Antiretroviral) [51] and 
CISAI (Italian Coordination Study for Allergies and Infections from HIV) [52] databases 
constitute the most important clinical cohorts for HIV studies in Italy. 
ARCA was started in 2002 by the HIV Monitoring Service at the University of Siena. It is 
a public database developed to investigate resistance to antiretroviral drugs used against 
the human immunodeficiency virus. The database contains patients’ treatment data, 
variations in the viral genome and the corresponding inferred susceptibility to the 
antiretroviral drugs, and the main infection markers such as plasma HIV-RNA load and 
CD4 cell counts.  
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ICONA was constituted as Foundation in 2007, but it began in 1997 as an observational 
study conducted on a wide cohort of HIV-positive individuals. Presently more than 14.500 
antiretroviral naïve patients are enrolled by the 50 institutions operating throughout Italy. 
The CISAI group was born in 1995 with the aim of studying clinical manifestations and 
the pathogenesis of allergic reactions to drugs, that in subjects with HIV infection occur 
with higher frequency than the general population. Since September 2002, CISAI 
SCOLTA is the first online pharmacovigilance program for new antiretroviral drugs. 
A fundamental aspect in clinical trials is the importance of communication between 
different research databases in order to expand the population under study, allowing the 
possibility of drawing on a broader set of information, to improve the knowledge about the 
disease, therapy or scope considered. In this perspective, interoperability between clinical 
structures with different architectures assumes great importance. The three hospitals 
involved in the Ligurian HIV network participate also in the three mentioned national 
clinical trials, by filling the platform through the dedicated web interfaces. In this way, 
when a patient undergoes a clinical test, all the research databases has to be manually 
updated; multiple manual input is time wasting and it may cause input errors affecting data 
quality. 
2.4 Clinical Decision Support System 
Decision support systems are tools that combine mathematical models and analysis 
techniques with traditional data processing functions in order to support decision makers. 
A decision support system includes two modules called EDP (Electronic Data Processing) 
and MIS (Management Information Systems). The EDP is the data processing system that 
is used to obtain information, while the MIS handles that information to provide references 
and possible choices in the decision options. A decision support system uses both these 
modules to elaborate the decision with the decision maker in interactive mode. Therefore, 
it does not attempt to provide the optimal solution, but the idea is to guide the decision 
maker through the best options in order to put him in the condition to make the optimal 
choice. 
In the medical field, the decision support is based on the information set that can help 
physicians to diagnose or to treat a patient’s health problem.  
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In clinical decision support systems, various methods are used to assemble information 
used for the process of decision-making, such as statistical method, neural network, rule-
based method, fuzzy logic rule-based, genetic algorithms. CDSS are classified into two 
major groups: knowledge based and non-knowledge based. Knowledge based CDSS use 
rules mostly in the form of if–then statements. Ruled-based CDSS exploit knowledge 
acquisition tool that facilitate the creation and maintenance of a knowledge base made of 
condition–action rule templates [11]. Non-knowledge based CDSS are implemented with 
the support of artificial intelligence, using machine learning algorithms to extract 
knowledge from a large number of data [53]. In this thesis I will focus on knowledge based 
CDSS. 
Knowledge based Clinical Decision Support Systems assemble the knowledge base with 
specific patient’s data by a dedicated engine, that uses a peculiar logic, to provide clinicians 
with guidance based on real-time data. Innovative clinical decision support systems work 
as clinical advisory systems that use epidemiological data together with expert knowledge 
(scientific evidence, guidelines and others) to provide real-time support to clinicians. These 
kind of systems are applied to different clinical situations, such as warning service for 
potential adverse drug interactions, interpretation of results of blood gas analysis and 
automated diagnostic medical programs. CDSS can contribute specifically to the 
improvement of the quality of care by providing the clinician with the best possible 
information easily and quickly accessible, helping him to choose between alternative tests 
and treatments for a specific problem to solve.  A CDSS system is designed to help directly 
or indirectly in clinical decision making, in a situation where the data of a given patient are 
crossed to a computerized knowledge database with the purpose of generating a specific 
evaluation for that patient, or to produce specific recommendations that are offered to the 
clinician as suggestions and advices. A Clinical Decision Support System can be defined 
as a system composed by a knowledge database and an inference engine that is able to use 
data to provide advices on specific cases. A knowledge database includes a set of 
systematically organized knowledge stored on a computer to make decisions or solve 
problems, while an inference mechanism indicates a procedure that operates on the 
representation of knowledge to complete new propositions. As already mentioned, 
Information and Communication Technology has become a fundamental tool for medicine, 
and the decision support system is essentially based on information technology. The main 
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information is that about the patient and that about the kind of problem and the relative 
knowledge. Traditional sources of patient information rely on paper files and have a long 
list of restrictions: illegibility, lack of completeness, lack of accuracy, lack of uniformity, 
inaccessibility, slow and unreliable transmission, lack of security and excessive physical 
volume of this documentation. To go beyond these shortcomings, the role of information 
technology, with its range of solutions, is definitely important, because of the potential to 
improve the accuracy of the information needed in making clinical decisions, to reduce the 
amount of time required to retrieve that information and finally to ensure that the 
information is accessible in the administration point of care. The key technology to improve 
the patient information is the aforementioned electronic medical record that stores complete 
information from a variety of sources (clinical, laboratory, from radiology, the pharmacy 
etc.). A fundamental feature that arouses from literature on this matter is that CDSS, to be 
truly efficient, should be smoothly integrated within the clinical information system, 
interacting with other components, in particular with the hospitals electronic health record, 
to avoid data manual entry, exploiting data already available in digital format. This kind of 
systems needs to directly interface with the electronic health record to access all the clinical 
data required [54]. This fundamental interaction between CDSS and EHR is deeply 
analyzed in the paragraph “Interoperability of CDSS and EHR”. 
The Information Technology is also used to retrieve, store and maintain scientific 
knowledge that will be used as base for the decision process. Electronic resources are 
generally easier to find and more up-to-date in respect of paper sources. The topic of 
knowledge representation is deeply analyzed in the dedicated paragraph.  
The process of healthcare information retrieval from hospitals EHR and the procedure of 
appropriate knowledge finding from clinical guidelines are not easy, because they require 
a correct integration of data coming from heterogeneous sources. Without the use of 
appropriate standards, errors could affect this operations, jeopardizing all the system. 
Moreover, without the use of healthcare standards, each user should implement specific 
interfaces to access the knowledge made available by the CDSS. The interoperability with 
external consumers should be facilitated through the adoption of a standardized service. 
In the literature a great number of CDSS implementations are described for different 
medical fields [30] [31] [32] [33]. Specifically, there are CDSS implementations also in 
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chronic infective diseases and in particular in HIV field, which have the potential to 
improve specialty medical care by monitoring laboratory results and patients follow-up 
[29] [35]. CDSS provide timely and efficient review of important new laboratory values 
and scheduling patient follow-up, generating alerts to notify HIV outpatient provider of 
adverse events. Alerts should effectively capture the attention of providers in a timely 
manner and they should be correctly rationed in order to avoid over-alerting that leads 
providers to ignore it. In the study conducted by Robbins et al [35] static alert and 
interactive alert have been compared on two groups of subjects, respectively the control 
group and the intervention group to control the suboptimal follow up. The figure 2.1 shows 
that the interaction alerts significantly improved the follow up control. 
 
Figure 2.1: Sub-Optimal Follow-up alerts were introduced by Robbins et al to improve retention in care in 
HIV infected patients. The Kaplan-Meier analysis of time to next scheduled appointment after the first Sub-
Optimal Follow-up alert in the intervention group reveals that the interaction alerts significantly improved 
the follow-up control. 
The importance of decision support systems is highly acknowledged as a key strategy to 
improve medical safety and quality of care. Despite the recognized potential to improve 
healthcare outcomes, examples of effective CDSS in routine clinical care are lacking, due 
to technical and social aspects [55]. 
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2.4.1 Interoperability of CDSS and EHR 
As before mentioned, CDSS assume great recognized importance as a mean to measure 
and control the quality of care, and the employment of computer-based CDSS has 
significantly improved clinical practice [38]. During the last years, CDSS has become 
increasingly important, raising clinical relevance [28] but, in the past, cultural and 
technological barriers have prevented a broad application of CDSS across the healthcare 
setting. The evolution in the adoption of health IT during the years, together with the 
resulting increase of availability of digital data from Electronic Health Records have played 
an important role in the evolution and adoption of CDSS. The avoid of manual data input 
that is error prone in respect to the re-use of digital available data on which infer decisions 
about patients assures better quality of the care delivered. This gave more confidence about 
this kind of systems among physicians that initially were suspicious about them. To re-use 
digital data already entered in the Hospital Information System, an interaction with other 
components, in particular with the Electronic Health Record, to access all the clinical data 
is required. A strong interoperability between the hospital EHR and the CDSS is the key to 
reach a most reliable decision support, that could aid in better diagnosis, reduce medication 
errors and improve practitioner performance [29]. A problem that arouses in the coupling 
of EHR and CDSS is the heterogeneity of clinical data sources and, as asserted by 
Kawamoto in 2010, the lack of a common information model and standardized clinical 
terminology force CDSS interfaces to have custom mappings between systems [38]. 
Moreover, CDSS require data at a higher abstraction level in respect to those contained 
into EHR. This problem is named “Impedance mismatch”. To overcome these problems, a 
virtual interface could be used between the EHR and the CDSS, in order to define mappings 
between it and the CDSS only once [54]. In this way, when a CDSS has to be connected to 
a new EHR system, only the mappings between the EHR system and the virtual interface 
are needed, without the need to modify the CDSS.  
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Figure 2.2: Linking a CDSS to different EHRs adapting the CDSS to each EHR 
 
Figure 2.3: Linking a CDSS to different EHRs through data views 
 
The specification for such a virtual interface have been developed by HL7 and it is named 
Virtual Medical Record (vMR). The HL7 vMR is a data model for representing clinical 
data relevant to CDSS, which entails providing clinicians or patients with clinical 
knowledge and patient-related information, intelligently filtered or presented at appropriate 
times, to enhance patient care [56]. The vMR aims to model and capture the totality of the 
clinical concepts that are relevant for CDSS in a simplified way and to omit non-influential 
concepts that are present in the EHR.  
  
29 
 
3 Methods 
3.1 Architectural approach 
3.1.1 Service-oriented architecture (SOA)  
Service-oriented architecture (SOA) is an architectural approach based upon the use of web 
services. A service is a piece of functionality made available by a service provider in order 
to deliver end results for a service consumer. These services communicate with each other: 
the communication can involve simple data passing or it could involve two or more 
services. A service consumer sends a request to a service provider, which returns a response 
containing the expected results. SOA emphasizes on breaking business processes into 
smaller blocks (services), thus addressing issues related to re-use, maintenance and 
integration [57]. 
SOA is increasingly utilized as an integration paradigm for HIS (Healthcare Information 
Systems). Healthcare organizations demonstrate ongoing efforts to reduce costs and 
improve the quality of their services through systems integration. The emphasis on 
standards based interface is a critical success factor for SOA. 
The number of interfaces grows exponentially as the number of connected systems 
increases, rising the economical expense for interface design, development and 
maintenance. SOA paradigm adoption reduces the number of point-to-point interfaces, thus 
reducing costs. Another advantage of SOA approach is the facilitation in software design 
and implementation, due to the decomposition of complex problems into smaller ones [58]. 
Software reusability is also a crucial point that can be achieved using Service Oriented 
Architecture, reusing existing IT resources and improving adaptability to new 
requirements. Among the recognized benefits of SOA, the improve in quality of data is one 
of the most important, especially in the medical field. In fact, the enhanced interoperability 
allows to produce more accurate and up to date information that are essential for the 
healthcare decision-making process [57]. 
Considering all the benefits described, a number of organizations have adopted SOA 
approach in health care environment, and in particular in Clinical Decision Support. and a 
literature review about it has been reported in 2014 by Salvador Rodriguez Loya et al [41]. 
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There are different possibilities for SOA-based architectural approaches, in particular six 
general architectural themes has been highlighted in this review: 
1. point to point 
2. enterprise service bus (ESB) 
3. service registry 
4. clinical guideline engine 
5. rule based engine 
6. service choreography and orchestration 
The review shows that all the architectural approaches presented can coexist within a SOA 
based implementation of a Clinical Decision Support.  
Contract standardization and scalability are both characteristics for which SOA integration 
can be seen as a process that enables interoperability. According to The Healthcare 
Information and Management Systems Society (HIMSS), interoperability is “the ability of 
different information technology systems and software applications to communicate, 
exchange data, and use the information that has been exchanged” [59]. There are three 
levels of interoperability: 
 Foundational interoperability: it allows data sharing, so that data sent by one 
system can be received by another system, but it does not imply that the receiving 
system can interpret it. 
 Structural interoperability: it is an intermediate level that defines the format of the 
data exchange and it focuses on the packaging of the data into standard messages. 
Specific standards, such as Health Level 7 for the healthcare field, provide guidance 
on how messages should be structured. 
 Semantic interoperability: it is the ability of two or more systems not only to 
successfully exchange information, but also to meaningfully interpret the 
information exchanged. It is granted only when both systems refer to a common 
information reference model. In healthcare field, the most known and used 
information model is RIM (Reference Information Model) of HL7. 
A SOA architecture itself does not guarantee complete interoperability. Semantic 
interoperability is essential for SOA architectures to grant consistency in the data exchange 
among service providers and service consumers. To address interoperability challenging in 
the context of SOA architectures, the Healthcare Services Specification Project (HSSP) 
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was formed in 2005 within a collaboration among Health Level Seven (HL7) and the 
Object Management Group (OMG) standards groups. 
3.1.1.1 Windows Communication Foundation (WCF) services 
Windows Communication Foundation (WCF) is a framework for building service-oriented 
applications in .NET. WCF combines different technologies by providing a unified 
programming model (and its API) for the implementation of interoperable applications, all 
based on shared standards, enabling the exchange of information even between non-
heterogeneous platforms. This new unified programming model was based on the SOA 
architecture guidelines. 
3.2 Standards 
3.2.1 Data sharing in clinical context 
The healthcare domain is very large, complex, and in continuous changing. During the 
process of data sharing through different healthcare institutions, many problems can arouse 
in the interpretation of the identities exchanged due to different formats, domains and 
geographical locations. Effective communication requires that both information sender and 
receiver share a common reference framework that enables all interactions to be 
unambiguously understood providing uniformity in the definition. One possible solution 
should be the developing of custom interface solutions for each problem, but in this way, 
it is difficult to adapt to new requirements. The heterogeneity of the clinical data sources 
should be overcome by the creation of a sharing framework through dedicated standard 
services in order not to modify the hospital systems architectures. Different methodologies 
exist to implement an interoperable system such as Health Level 7 standard. 
Interoperability includes two components: syntactic or functional interoperability and 
semantic interoperability. Syntactic refers to the structure of the communication, while 
semantics refers to the meaning of the communication, as dictionaries or thesaurus. To 
represent clinical concepts and constructs within the HL7 framework, a standard 
vocabulary is needed to populate the model with meaningful data. A standard list of codes 
represents many different clinical concepts. Without semantic interoperability, information 
may be interchanged but there is no certainty that the receiver can understand it. 
Terminology only provides a standardized set of terms, there is the need to provide a 
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standard structure for data and specifications about the correct use of these terms in this 
structure. 
The existing healthcare standards address both components of interoperability and are 
grouped into the following categories [41]: 
 Terminology standards: vocabularies provide specific codes for clinical concepts 
such as diseases, medications, allergies, and diagnoses. Examples of terminology 
standards are LOINC (Logical Observation Identifiers, Names and Codes) for 
laboratory results, SNOMED (Systematized Nomenclature of Medicine) for 
clinical terms, ICD (International Classification of Diseases) for diseases and ATC 
(Anatomical Therapeutic Chemical) codes for drugs. 
 Document standards: to structure information in clinical documents. Examples 
are The Continuity of Care Record (CCR), the Virtual Medical Record (vMR) of 
HL7 to structure patient’s data for decision support and the HL7 Clinical Document 
Architecture (CDA) r2 which specifications are subdivided according to the type of 
document to be developed (discharge letters, referrals, consultation notes and image 
or laboratory reports). The CDA semantics is based on the HL7 V3 RIM, the HL7 
V3 methodology and controlled vocabularies. CDA documents have a header and 
a body. The header set the context of the document for management and 
communication purposes. The body of the document may be unstructured 
(NonXMLBody) which could contain any content or structured (StructuredBody) 
which contains coded sections and the narrative block. In the header are 
distinguished the various participants (author, authenticator, performer, custodian 
and subject of the performance). The body may also contain external attachments. 
 Conceptual standards: provide a framework to model and describe clinical data 
and the surrounding context. For example the HL7 Reference Information Model. 
The reference model is used by all local applications to map their structures in order 
to successfully communicate with other local applications. 
 Architecture standards for web services and exchange of clinical documents: 
to define the processes involved in data distribution and storage. Examples include 
the standards developed within the Healthcare Services Specification Project 
described in the next paragraph. 
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3.2.2 Healthcare Services Specification Project (HSSP)  
The Healthcare Services Specification Project (HSSP) was formed in 2005 within a 
collaboration among Health Level Seven and the Object Management Group standards 
groups [60]. The objective of the HSSP project is to produce standards that define the 
services’ interfaces, functions and behavior supportive of the healthcare sector based on 
SOA principles. HSSP aims at the standardization of services involved in health processes, 
facilitating the development of a set of standard interfaces. The HSSP standardization cycle 
produces two specific levels of service: Service Functional Model (SFM), managed by HL7 
International and the Service Technical Model (STM), managed by OMG. The SFM is a 
specification of the functionality of a service; it does not specify any technology or platform 
because it is implementation-independent. The “business capabilities” and “profiles” 
sections provide the core normative service description. Each business capability describes 
a specific action that the service must perform, resulting in one or more operations. A set 
of profiles are defined to cover specific functions (functional profile), semantic information 
(semantic profile) and overall conformance (conformance profile). The functional profile 
consists of a list of all the operations defined within the service; the sematic profile defines 
the meaning of the entities and their properties, and could provide cross-references to the 
RIM based domain models; the conformance profile is a machine testable specification of 
all conformance issues. As displayed in the diagram in figure 3.1, after the development of 
a Service Functional Model, the next step is the adoption of the SFM as a Draft Standard 
for Trial Use. To be adopted as a draft standard, the HL7 specification has to be presented 
to the HL7 national membership for the ballots. After the adoption of an SFM as an HL7 
draft standard, a Request for Proposals (RFPs) for a technology-neutral Platform 
Independent Model and one or more technology-specific Platform Specific Models for the 
service are generated under the supervision of OMG group. The final step is the revision 
of the adopted standards based on real implementations. Presently, there are some HSSP 
products for which SFM and STM has been developed. 
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Figure 3.1: HSSP standardization cycle. Two specific levels of service are defined: the Service Functional 
Model (SFM) is managed by HL7 International and the Service Technical Model (STM) is managed by 
OMG group. 
3.2.2.1 Identification and Cross-Reference Service (IXS) 
The Identification Service (IS) also known as the Identification and Cross-Reference 
Service (IXS), manages the identifying information for different kind of entities, such as 
people, organizations, devices and others. It provides means for managing, defining and 
updating identities and systems that share a standards interface to maintain a common 
description of each entity. The Service Functional Model specifications refer mainly to 
patients as entity, because it is the most common entity that generates problem to a wide 
audience, but similar functionalities and scenarios are relevant also to other types of 
entities. The main problem on which this standard is focused is the merging of all the 
identification codes (IDs) that are assigned to a person by each healthcare facility during 
lifetime. Having a standard for the process of identification of a patient considerably 
improves the quality of care. 
3.2.2.2 Retrieve, Locate, Update Service (RLUS) 
The Retrieve, Locate, Update Service Release 1 (RLUS) provides means for interacting 
with a system that exposes the data of interest, providing a standardized way of location, 
update, and retrieval of that content. RLUS objective is the definition of service interfaces 
for the creation, registration, update, search, discovery, retrieval and query of clinical and 
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health resources. The main operations involved are to locate, get, list, put, initialize and 
discard resources. 
3.2.2.3 Decision Support Service (DSS) 
The Decision Support Service Release 1 (DSS) is a service that provides decision support 
to clinicians based on real-time patients’ data. Decision support systems could be highly 
effective and improve clinical practice. A DSS contains many “knowledge modules”, 
which are able to drive machine-interpretable conclusions about a patient basing on his 
data. When requesting for evaluation, the client specifies the knowledge modules to be 
used, and provides the patient’s data that are required by the knowledge modules. The DSS 
returns the evaluation made on the patient in a format that is pre-defined for the used 
knowledge modules. 
3.2.2.4 Common Terminology Services Release 2 (CTS2) 
The Common Terminology Services Release 2 (CTS2) is a terminology service that should 
provide a standardize interface for the usage and the maintenance of terminologies. The 
service interface allows the query, definition and modification of the different terminology 
components, establishing a common model. It specifies the interactions between 
terminology providers and consumers, managing revisions, corrections and extensions 
through versioning. 
 
3.2.3 Knowledge representation in CDSS 
The CDSS relies on the data stored in a database to drive conclusions about a patient’s 
problem basing on a knowledge base. The type of logic to be used derives from the kind of 
knowledge base implied. Ruled-based CDSS use some knowledge acquisition tool that 
facilitate the creation and maintenance of a knowledge base made of condition–action rule 
templates [11]. 
The knowledge used as basis for decision support should have an adequate scientific 
evidence, and any deficiency in the quality or relevance of it could affect the CDSS 
effectiveness. Therefore, knowledge basis should be extracted from the research literature, 
guidelines and up-to-date practice-based sources [12]. Once extracted from the most 
appropriate sources, most frequently from clinical guidelines, knowledge has to be made 
easily accessible in machine interpretable format to be computationally digested by the 
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software. A knowledge management system is therefore needed to extract, maintain, update 
and share computer interpretable evidence-based knowledge.  
3.2.3.1 Computer interpretable clinical guidelines  
Clinical Practical Guidelines are “systematically developed statements that can be used to 
assess the appropriateness of specific health care decisions, services, and outcomes”, as 
defined in 1990 by the Institute of Medicine [61]. 
According to [62] clinical guidelines should accomplish 5 tasks:  
1. Making of decision: one of the main purposes of the clinical guidelines is the 
support to be provided to physicians in making a decision 
2. Sequencing of actions, that is to support the structuring of actions and decisions 
and, therefore, suggest the temporal order of the actions or the possible sequence 
3. Setting of goals: indicates the ability of the physician to identify, through the 
guideline, the goals to be pursued in applying a specific treatment to a clinical case 
4. Interpretation of data: the application of a guideline to an individual always requires 
customization of the abstract and general concepts described 
5. Refinement of actions. 
These five tasks are interdependent, and the links among them are represented in figure 
3.2: the continuous line arrows indicate the sequence of actions and decisions, the arrows 
in dashed line indicate the choice between different alternatives, while the rounded arrows 
indicate data flow. 
 
Figure 3.2: Schema representing the five tasks that a clinical guideline have to accomplish. These five tasks 
are interdependent: the continuous line arrows indicate the sequence of actions and decisions, the arrows in 
dashed line indicate the choice between different alternatives, while the rounded arrows indicate data flow. 
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Computer-interpretable clinical practice guidelines (CIGs) are text-based clinical 
guidelines converted to machine executable CDSS rules through the use of a guideline 
representation model. Guideline representation models are representation languages and 
frameworks that can be used to model guidelines and protocols in a computer interpretable 
and executable format. Different kind of guideline representation models have been 
developed in the last decades, as represented in figure 3.3. 
 
Figure 3.3 Time evolution and conceptual links between the different guideline representation models 
The guideline representation models mentioned in figure 3.3 are designed for the same 
goal, and they have many common points, but each of them has a different approach.  
In the following paragraphs, a brief description of the most popular guideline representation 
models is reported. 
3.2.3.1.1 Arden Syntax 
The Arden Syntax for Medical Logic Modules (MLM) is a language for encoding medical 
knowledge bases that consist of independent modules [63]. A MLM is a software module 
that, when implemented on a clinical information system works on a database and provides 
warnings and alerts for physicians. The purpose of an MLM is to provide the knowledge 
required to start an action on data available in a database. An MLM is an ASCII file with 
the slots grouped into three categories: maintenance, library and knowledge. The 
maintenance slot defines the name, author, origin, version, and the validation information. 
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The library slot defines the connections with other sources of knowledge, comments, and 
keywords for searching. The slot knowledge, which is the substance of MLM, contains the 
current medical knowledge. 
The Arden Syntax adopts a procedural paradigm, in which each independent module does 
not provide a list of facts, but it contains the necessary procedures to recover, filter and 
analyze data, make a decision or carry out a specific action. The procedural modules, 
therefore, do not indicate what to do but how to do it. The Arden Syntax uses a frame made 
in blocks, without the use of loops and therefore the structure to be used is the classic if-
then-else. The data types are those fundamentals of the most common programming 
languages, such as integer, real, char, pointers, strings, arrays and lists. Lists cannot be 
nested. A key assumption is that the data come from an existing electronic clinical database, 
without interactive input. 
3.2.3.1.2 GLIF 
“The Guideline Interchange Format (GLIF) was created by the InterMed collaboration, a 
joint project of biomedical informatics groups at Harvard, Columbia, and Stanford 
universities, to serve as a common representation format for CIGs” .[64]. The researchers 
analyzed the implementation of MLM Arden Syntax, and other previous systems in order 
to seek what were the possible common characteristics and to analyze those that best 
correspond to the optimization criteria. The first version of GLIF was rather limited and it 
was not widely disseminated. 
GLIF2 [65] was designed to support guideline modelling as a flowchart of structured steps 
which represented clinical actions and decisions. GLIF2 was published in 1998 and consists 
of two main parts: a model to GLIF objects and GLIF syntax. 
The GLIF2 model allows specification of a guideline as a flowchart of steps ordered 
temporally. The steps represent actions or clinical decisions and, at the same time, 
ramifications and synchronization steps are used. There are four types of steps:  
1. Action steps: specify clinical actions that has to be undergone during the care 
process 
2. Decision steps: could be conditions or branches 
3. Conditional steps: contains a condition, or criterion, which is a logical statement 
that may be evaluated to true or false 
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4. Branch steps: direct flow to multiple guideline steps 
GLIF2 presents a few limitations, for example some important attributes do not have a 
structured representation and some concepts and flow-control constructs are missing. 
GLIF3 is the last revision that overcomes the previous difficulties. In particular, object-
oriented expressions and query language were added and the flow-control was improved 
[64]. The GLIF3 model consists of classes, their attributes, and the relationships among the 
classes, all of which are necessary to model clinical guidelines.  
 
Figure 3.4: A high-level view of the major classes in GLIF. The lines between the classes denote 
relationships: a diamond-shape arrowhead indicates an aggregation or containment relationship, and a 
triangle shape indicates inheritance. 
GLIF3 supports representing clinical guidelines in three levels of abstraction:  
1. Conceptual level: the guideline is represented as a flowchart. 
2. Computable level: completeness and logical consistency of the guideline can be 
checked. The expression syntax, the medical actions and the algorithm flow are 
defined. 
3. Implementable level: the guideline is ready to be incorporated within environments 
of institutional information systems. 
Action and decision classes of the GLIF ontology reference patient data items and medical 
concepts. These concepts are formally defined by standard controlled vocabularies (e.g., 
UMLS, LOINC, SNOMED CT) and standard medical data models. A reference 
information model defines the basic data model for representing medical information and 
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it is essential for guideline execution and data sharing among different applications and 
different institutions. The default reference information model that GLIF3 supports is 
HL7’s Reference Information Model (RIM) version 1. Core GLIF defines how medical 
data items are structured and how they relate to medical concepts. 
 
 
Figure 3.5: Core GLIF class diagram 
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The Guideline class of GLIF ontology is used to model clinical guidelines and sub-
guidelines. GLIF’s guideline class specifies the algorithm, which is a flowchart of guideline 
steps, maintenance information such as author, guideline status, last modification date, and 
version. The intention of the guideline, the eligibility criteria, didactics, and the set of 
exceptions that interrupt the normal flow of execution are specified too. The guideline also 
defines patient data items that are accessed by it and parameters that the guideline passes 
in and out to other sub-guidelines. Figure 3.6 reports all this information. 
 
Figure 3.6: The GLIF guideline package 
3.2.3.1.3 ASBRU 
Asbru has been developed by the Asgaard project led by the Vienna University of 
Technology and Stanford Medical Informatics and it was first introduced in 1998. Asbru 
is a task-specific and intention-based language to represent clinical guidelines as time-
oriented skeletal plans [66]. Skeletal plans provide a powerful way to re-use existing 
domain-specific procedural knowledge. Clinical guidelines can be seen as a set of 
schematic plans for the treatment of patients who have a peculiar clinical condition. In 
Asbru, the following parts of a plan can be specified: preferences, intentions, conditions, 
effects, and plan body (actions). Plans might be executed in sequence, or in parallel (all of 
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them or some), or in a particular order, or periodically. Explicit intentions and preferences 
can be stated for each plan separately. 
 
Figure 3.7: The Asbru plan ontology structure 
3.2.3.1.4 GEM 
The Guideline Elements Model (GEM) is an XML- based guideline document model that 
can store and organize the information contained in practice guidelines. GEM offers a 
translation of documents, written in natural language, in a computer-processable format. 
GEM is structured in a hierarchy with more than 100 elements with 10 major branches: 
Identity, Developer, Purpose, Intended Audience, Target Population, Method of 
Development, Testing, Revison Plan, Implementation Plan, and Knowledge Components. 
 
Figure 3.8: GEM hierarchy structure 
3.2.3.1.5 PROforma 
The PROforma System, designed by Fox in 1998, to represent Guideline, using a logic-
based approach. The Guidelines are modeled in terms of an ontology task (task, action), 
consisting of decisions, actions, inquiries and plans, which, in turn, can be further 
decomposed into more detailed tasks. All the PROforma system tasks have the following 
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attributes: trigger, goal, precondition and postcondition. Tasks are described by their 
scheduling constraints (list of limitations), preconditions and postconditions. A task 
manager that performs a task can write new facts from a global database, and then perform 
the activation of other tasks, through evaluation of their preconditions. Any number of tasks 
can be activated simultaneously.  
3.2.3.1.6 GELLO 
GELLO is a standard object oriented query and expression language for clinical decision 
support [67]. It is a language to write expressions and make queries on medical data. 
GELLO expressions can be shared among institutions with different systems without the 
need of rewriting. GELLO programs refers to an environment that contains a list of 
predefined classes which can be used with their properties and methods (attributes and 
operations).In general, the data model supplied to the GELLO program will have a number 
of classes which represent components of the data model. 
GELLO expressions can be embedded at any point where decision rules, eligibility criteria, 
patient state specifications or guidelines are needed. For example, decision points in the 
GLIF flowchart run automatically by using GELLO to evaluate computable decision 
criteria on patient’s loaded data. GELLO is compatible with the Reference Information 
Model RIM of HL7. 
 
Figure 3.9: GELLO and its relation to Arden Syntax, GLIF, RIM and other DSs and KBs. GELLO query 
and expression languages can be embedded into various tools to provide the mechanisms for access and 
manipulation of Object Oriented data. 
There are two phases in embedding GELLO code into decision support system: the pre-
execution phase, which consists in parsing and compiling, and the execution phase, which 
consists in requesting and evaluating patient’s data. The execution phase consists of three 
steps, which are reported in figure 3.10. In the first step, GELLO expression is considered. 
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If it is an evaluation then it goes to step three, while if it is a request of patient’s data it goes 
to step two. In the second step, the expression is an internal call to the DBMS requesting 
information about a patient. The DBMS is an intermediary database compatible with HL7 
RIM (such as vMR) that handles the request, retrieves the information and returns it to the 
application. Ad-hoc mapping software extracts data from the institution database and stores 
it into the DBMS. Institution’s databases where patients’ data are stored are organized in 
specific ways that may not be compatible with other institution’s data organization. In the 
third step, if all needed information is available, the engine evaluates the expression and 
returns the result to the application. 
 
Figure 3.10: The execution phase of GELLO consists into three steps: evaluating GELLO expressions, 
requesting data and evaluating data. 
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3.2.3.2 Lifecycle 
To be effective, clinical guidelines have to be integrated into the clinical workflow, to assist 
physicians in real time providing patient specific advices. Clinical guidelines are inferred 
by a systematic review of the evidence coming from the results of the most recent clinical 
trials. The lifecycle of the computer interpretable guideline shall consider the periodic 
revision of the related clinical guideline, as the requirements change over time because new 
information sources become available and new experience is gained. According to Mor 
Peleg [68] the lifecycle of the development of clinical computer interpretable guidelines 
passes by three phases “Analysis and design”, “Deployment and usage” and “Maintenance” 
which in total consist of eight steps: 
1. Definition of modelling language 
2. Knowledge acquisition and specification 
3. Integration of computer interpretable guideline  into EHR 
4. Validation and verification (the testing phase is usually supported by execution 
engines) 
5. Use of computer interpretable guidelines in CDSS to deliver decision support 
6. Exception handling 
7. Maintenance  
8. Sharing 
In figure 3.11 the interconnections between these steps are presented. 
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Figure 3.11: Clinical guidelines lifecycle 
The representations of clinical practice guidelines can be classified into three categories: 
document models, decision trees and probabilistic models, and task-network models [68]. 
The Guideline Elements Model is the best known example of the first category, and it is an 
XML-based knowledge model for guideline documents. Guideline representation that 
belongs to the second category represents the guideline’s algorithmic knowledge as a 
decision tree, which is a graph that uses a branching method to illustrate every possible 
outcome of a decision, sometimes applying a probabilistic model. The third category allows 
to execute the represented knowledge against patient data by means of an execution engine. 
A variety of task-network languages have been developed such as GLIF and PROforma.  
The critical phase is the development and usage phase. The development of computer 
interpretable guidelines is facilitated by the use of a guideline editor. Some guideline 
editors have been realized to facilitate the process of describing clinical guidelines by 
means of a graphical interface using flow charts to describe the logical sequence of action 
and rules. Guideline editors translate the flow charts edited by the users into a hidden code 
usually in a standard language as XML, since standard format enables to better share the 
clinical knowledge embedded within guidelines. RetroGuide [69] is an analytical 
framework that has a graphical flowchart and a hidden code layer. Also users with low 
computer skills can design flowcharts. The code is hidden behind the nodes and arrows of 
the flowchart and points to EHR data through references to modular applications. Together 
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Workflow Editor produces XML files based on the XPDL (XML Process Definition 
Language) specification, and supports every workflow engine that knows how to interpret 
standard XPDL, for example Together Workflow Server.  
Before its release, the computer interpretable guidelines produced with the editor has to be 
successfully validated. The validation phase can be performed using an execution engine 
that interprets and executes the clinical guidelines created. Some editors have intrinsic 
guideline execution engine that allows to test the condition-action-rules described in the 
graphical interface on real data, also available in standard formats. This is the case of GLIF 
Editor that was developed by Medical-Objects. The GLIF Editor provides clinicians with 
an intuitive flowchart interface. Decision points in the GLIF Editor can run automatically 
by adding GELLO code to evaluate computable decision criteria by querying patient's data. 
In this way, queries and expressions share a common object-model because the results of 
queries are used in decision criteria and other expressions. GLIF Editor allows to test the 
guideline automatic decisions steps which encapsulate GELLO code by loading patient’s 
test data in HL7 v2 format. Patients’ data loaded are mapped according to the RIM model 
and can be accessed by GELLO code:  
let Hb_code = factory.codedvalue('718-7','LN') 
let Hb_obs = observation->select(code = Hb_code)->sortby(absolutetime)->last() 
GELLO is the execution language of GLIF editor. The execution language is an important 
issue of the executable representation of guidelines to formalize expressions. According to 
Kolesa [70], an execution language consists of four sublanguages with different roles: the 
arithmetic expression sublanguage, the query sublanguage, the data manipulation 
sublanguage and the date related functions.  
3.2.4 Standards for CDSS: HED initiative 
Health eDecision (HeD) is an initiative of the Office of the National Coordinator‘s 
Standards & Interoperability Framework [23]. HeD does not aim to create a new standard, 
but its intent is to identify, define and harmonize already existing standards involved in 
clinical decision support field. The main standards considered are:  
 HL7 Virtual Medical Record (vMR), a data model for representing patient’s data 
that are analyzed and/or produced by CDS engines 
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 HL7 CDS Knowledge Artifact, for knowledge artifact specifications 
 HSSP HL7 Decision Support Service (DSS) 
This initiative actually supports two general use cases. The first use case “CDS Artifact 
Sharing” is about knowledge artifact exchange and it specifies how to structure medical 
knowledge in a sharable and executable format. The second use case “CDS Guidance 
Service” relates to the exchange of information that allows the delivery of the results 
derived from the execution of clinical decision support, focusing on how a clinical decision 
support system receives data and returns conclusions and recommendations. 
3.2.4.1 vMR  
The virtual Medical Record is a standard for the representation of medical knowledge for 
CDS developed by the HL7 group. It is a RIM based data model that represents the data 
that are analyzed and/or produced by CDS engines, thus allowing interoperability between 
different CDS and medical data sources. 
González-Ferrer et al. assert that the vMR model is bi-dimensional, in which one dimension 
represents the type of clinical information (Procedure, Observation, Problem, Substance 
Administration, Goal, Encounter) and a second one the workflow moment (Proposal, 
Order, Event) [71]. 
The vMR can be considered a simplified representation of the clinical record that is suitable 
for a CDS knowledge engine to directly manipulate in order to derive patient-specific 
assessments and recommendations. With respect to the CDA, it avoids multiple nesting of 
concepts. It uses a simplified version of the HL7 version 3 data types release 2, with a 
particular attention to the management of the null flavors. It employs a more intuitive 
representation of concepts, using alternate methods to express the concepts of mood codes, 
negation indicators and inversion indicators. 
The vMR class diagram is represented in figure 3.12. Substantially, the vMR class can refer 
to a particular template, among those listed in the draft standard for trial use “HL7 Version 
3 Standard: Virtual Medical Record for Clinical Decision Support (vMR-CDS) Templates, 
DSTU Release 1”. The class vMR has an EvaluatedPerson type attribute, which is a Person 
(inherits from Person class) which, in turn, inherits from Entity class. The EvaluatedPerson 
can have an indefinite number of ClinicalStatement attributes. The ClinicalStatement class 
is a concrete class that can be used as it is or it can be specialized as needed into more 
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specific clinical statements, such as ObservationResult, SubstanceAdministrationEvent 
and Problem. 
 
Figure 3.12: vMR class diagram 
 
3.2.4.2 HSSP HL7 Decision Support Service (DSS)  
A decision support service receives patient data as input and returns patient-specific 
conclusions as output. HL7 DSS is part the Healthcare Service Specification Project, as 
already mentioned in the HSSP paragraph. The DSS is a custodian of knowledge modules 
(KM); a knowledge module is a package of knowledge that can be applied to patient’s data 
to derive conclusions about the patient under evaluation. The DSS is called by a client 
application, which specifies the knowledge module which is interested in, and supply the 
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related patient’s data. In return, the DSS sends its conclusions in a specified format. Each 
knowledge module takes part in the related lifecycle according to its status. Status are: 
 DRAFT: when a KM is created and can be modified. Every time the status changes 
to draft, a new version is created. 
 DEFINED: the KM is in unit test. 
 REJECTED: the KM has been tested unsuccessfully. A new draft is required. 
 APPROVED: the KM has been tested successfully and can be deployed. 
 PROMOTED: the KM has been deployed. 
 RETIRED: the KM was deployed or approved but is no longer active. 
The diagram in figure 3.13 represents the lifecycle. 
Figure 3.13: knowledge modules lifecycle 
The DSS service is called by a client that requires a patient evaluation, specifying which 
knowledge modules to use. The logic sequence of calls are reported in the diagram in figure 
3.14. 
51 
 
 
Figure 3.14: Logic sequence of calls to the DSS service 
The normative provides a WSDL (Web Services Description Language) and associate XSD 
files that describe the Platform Specific Model (PSM) for SOAP XML Web services. The 
WSDL is a formal language in XML format used to describe the public interface of a web 
service. A WSDL document contains information about operations provided by the 
service, the communication protocol to use to access the service, the size of accepted 
messages for input and output returned by the service and related data, the constraints 
(bindings) of the service and the service endpoints which usually correspond to the 
addresses in URI format. 
The DSS WSDL provides three endpoints: query, evaluation and metadata discovery. 
Metadata discovery interface: allows a consumer to get the list of all the profiles supported 
by the DSS and then to use the other operations to identify the capabilities of the service. 
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Figure 3.15: Operations defined in the MetadataDiscovery interface of DSS service 
The query interface enables the characterization and discovery of all knowledge modules 
in the platform. 
 
Figure 3.16: Operations defined in the Query interface of DSS service 
The evaluation interface enables data evaluation using knowledge modules. 
 
Figure 3.17: Operations defined in the Evaluation interface of DSS service 
To ensure a minimum level of interoperability two functional profiles are defined in the 
normative [72]: HSSP Simple Evaluation DSS Functional Profile and HSSP Complete DSS 
Functional Profile. Figure 3.18 reports the operations supported by those functional 
profiles. 
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Figure 3.18: Operations supported by HSSP Simple Evaluation DSS Functional Profile and HSSP 
Complete DSS Functional Profile 
In the normative, two separate WSDLs are provided to correspond with the two functional 
profiles. 
Evaluate is the main operation of the DSS service. It takes a complex Evaluate type as input 
called evaluateRequest and returns a complex EvaluateResponse type object. The payload 
for the request is the clinical data that is evaluated by the DSS. The payload for the response 
is the guidance provided by the DSS. In both cases the data model that could be used is the 
vMR. Moreover, compliant DSS implementations shall use HL7 vMR templates as defined 
in [73] when an appropriate template is available. 
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Figure 3.19: Evaluate is the complex type that is given as input to the Evaluate operation. The figure reports 
the Evaluate class composition. 
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Figure 3.20: EvaluateResponse is the complex type that is returned by the Evaluate operation. The figure 
reports the EvaluateResponse class composition.  
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4 Results 
My PhD project is inspired by the innovative idea of LHS. It could be seen as a composition 
of three layers, where each layer is developed above the previous one. The first one consists 
in the setting-up of a SOA-based architecture to enable data collection from sparse facilities 
into a single repository. This would allow medical institutions to share information without 
an increase in costs and without the direct involvement of users. The second layer uses the 
data collected from the healthcare institutions involved to perform multi centric clinical 
trials at regional and national level. The third layer relies on the knowledge acquired 
through the conduction of clinical trials, put together with clinical guidelines directions to 
drive decision support. The benefits of using a decision support system in clinical practice 
should affect the quality of the care delivered, thus closing the LHS cycle. 
The architecture built allows the integration of many healthcare facilities into a larger 
system, ready to data sharing. In order to allow interoperability among different healthcare 
facilities, suitable medical informatics standards were applied to the system developed. 
Thanks to this system, real-time learning from patients’ experience can be reached, because 
the system can achieve all historical data irrespective of their physical location.  
It is evident how this system could be of peculiar importance in chronic diseases, where a 
significant amount of data is periodically collected and analyzed. Specifically, I put in 
practice this system in chronic infectious diseases data management in the Ligurian setting, 
where it is fundamental to enroll large number of patients in order to implement clinical 
trials.  
In this and other domains, all the collected data will provide wide and scientifically valid 
samples that can then be used to infer knowledge, in order to support chronic care 
management and treatment decisions. The overall architecture of the system developed is 
displayed in figure 4.1. 
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Figure 4.1: Recap of the architecture developed. The red-bricked squares represent the firewalls of hospitals 
and institutions involved. Non-proprietary systems are highlighetd with grey bars. The software 
applications developed within this project are of three types: Web Sites (in grey), Console Applications (in 
black) and Web Services (in lightblue). Single arrowheads represent monodirectional data-flow (read-only 
permissions), double arrowheads represent bidirectinoal data flow (read and write permissions). Details 
about the system developed and the communication among the components involved are explained in the 
next paragraphs. 
  
58 
 
4.1 First layer: automatic clinical data flow in the 
Ligurian HIV Network 
The first layer of this project has seen the finalization of a prototype of interoperability at 
an intra-regional level through the development of an infrastructure based on standardized 
services starting from the LHN architecture.  
The LHN was originally conceived as a mere web platform to enable the collection of data 
from HIV patients using a web interface, in order to perform multi-centric clinical trials at 
a regional level. For the first year, the platform was consistently used for its initial scope, 
supporting about half a dozen local studies. Routine use of the platform, together with the 
intention to address the well-known problem of errors due to manual data input into web 
interfaces, led to a consecutive gradual evolution of the system. The leading idea was that 
clinical data, already available in digital format in the LIS (Laboratory Information System) 
and other components of the Hospital Information System (HIS) could be extracted and 
automatically exported to the LHN database. In this way, patients’ laboratory data could 
be updated daily without human intervention. For this purpose, the architecture developed 
supports a standardized and automatic transfer of data from hospitals EHRs towards a 
central repository. With this system, data collected in hospitals’ EHRs can be electronically 
transferred to a single registry, thus eliminating double data entry and reducing the 
resources required for care centers to participate in single clinical trials. 
This automatic data retrieve architecture currently involves the chronic infection diseases 
wards of three hospitals in Liguria, but thanks to standardization, it is ready to new 
enrollments. The achieved structure allows clinical data to be shared between the 
authorized healthcare facilities.  
The adoption of standardized solutions allows interoperability among the healthcare 
facilities involved in the project. The current architecture is an implementation of the 
Healthcare Services Specification Project (HSSP) proposed by HL7 and OMG (Object 
Management Group) standard groups, which is based on SOA (Service Oriented 
Architecture) approach. HSSP Retrieve, Locate, and Update Service (RLUS), is used at 
present to manage patients’ data; HSSP Common Terminology Services - Release 2 
(CTS2) is currently under construction by some colleagues in the laboratory and, when 
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finished, it will be usefully integrated in the actual architecture to administrate the 
definition of semantics and syntax. 
To manage patient administrative data, the Patient Topic within the Patient Administration 
domain of HL7 v3 was taken into account; in particular, information about patients was 
mapped through a “PRPA_MT201301UV.PRPA_MT201301UV02Patient” object. To 
share clinical data between the healthcare facilities the HL7 v3 Clinical Document 
Architecture R2 (CDA R2) standard was adopted.  
To support semantic interoperability among different care facilities, waiting for the CTS2 
service to be ready, a harmonization of hospital local terms was manually performed. In 
particular, the LOINC (Logical Observation Identifiers Names and Codes) vocabulary was 
adopted to translate laboratory terms. To univocally identify diseases the International 
Classifiers of Disease (ICD10) was used, as indicated by World Health Organization 
(WHO). 
In order to connect the authorized Hospital Information Services (HIS) to this architecture, 
technically different client applications were implemented, because each hospital had 
different access policies. Specifically, each HIS adopted its own strategy to provide access 
to its content: through a web service or by direct access to the database. 
In the first case, after authentication and authorization control, data were made available 
on demand in different formats (e.g. XML (eXtensible Markup Language), JSON 
(JavaScript Object Notation)). In the second case, the database administrator (DBA) 
created a specific user profile with reading permissions to access database or a restricted 
part of it, so that information could be directly extracted thought queries or store 
procedures. In this case, the client application needs to be installed within the hospital LAN 
(Local Area Network) for security policies. 
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Figure 4.2: Qualitative schema of the architecture developed to support automatic data collection from the 
LIS of the three hospitals involved. The table reports the list of the categories of clinical data extracted from 
LIS and the related year of PhD in which the single functionality was employed. 
The Galliera Hospital offers several services to access patients' clinical data, including a 
data management service to access laboratory test results. After authentication, data are 
available on demand in XML or JSON proprietary format. On the other hand, IRCCS AOU 
San Martino IST and Sanremo hospitals do not share data through services, thus the only 
way to access data is to extract them directly from the LIS, installing the console 
application inside the hospital firewall. 
During the second year, the network on which the learning health system is based has been 
widened: the automatic and daily updated flow of data have been enriched with 
microbiologic tests, antibiotic resistance tests to bacteria, serology data and immunization 
administration. 
To monitor immunization administration, it is essential to collect data in a unique regional 
vaccine registry. However, in Liguria there is no such system. Each of the five local health 
units ASLs (Azienda Sanitaria Locale) relies on a different private company to manage 
immunization information. The “Ligurian Vaccination in HIV Project” was developed in 
collaboration with the Department of Health Sciences (DiSSal) for the monitoring of 
vaccination coverage in HIV population [74]. Vaccine administration data such as injection 
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date, typology and dose are extracted from the ASL vaccine registry, structured according 
to indications present in the immunization section of the HL7 CCD document and then 
recorded into the LHN.  
The supervision of immunization coverage can be evaluated through the association 
between the immunization information and the antibody titers and serological data gathered 
from the hospitals’ LIS. The process of data extracting is shown in figure 4.3. 
 
Figure 4.3: UML sequence diagram showing update of LIS data and vaccination information 
One problem, faced within this project, was the harmonization of patients’ identification 
from separate systems. Specifically, each hospital has its own administration system, where 
patients are identified by a tax code, a hospital ID and a regional ID. The hospital ID is 
used for intra-hospital data exchange, for example to identify patients’ laboratory exam 
results. The regional ID is used when data needs to be exported outside the hospital, for 
instance to make periodical regional reports. Even if using both IDs, it is not possible to 
infer patient identity, without a direct link to the hospitals’ demographic system. In order 
to properly identify patients without knowing the related identity, the region Liguria should 
implement an identification web service. Waiting for the region to implement such a 
system, I developed a repository with the mappings of patients’ IDs. 
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Currently 4338 patients from eight different hospitals are involved in the LHN. Among 
them, data from 1851 patients from San Martino hospital, 1241 from Galliera hospital and 
267 from Sanremo hospital are automatically updated using the described tool. 
 
Figure 4.4: Number of exams registered in the Ligurian HIV Network distributed per type and years. 
The difference between the data collected automatically and the data collected manually 
through the web interface, regarding the mean number of laboratory tests registered each 
year and the mean number of parameters registered in a single laboratory test is shown in 
table 4.1. 
 Mean no. of lab tests per year Mean no. of parameters per 
test 
Automatized centers 10679 41 
Non automatized centers 1910 31 
Table 4.1: Difference in the quantity of data registered between the two scenarios 
Without automatic data transfer, a complete report of the laboratory activity for all the 
patients involved in a web network such as the LHN is only achievable due to a strenuous 
human effort and the allocation of great resources, as the numbers in table 4.1 attest. Using 
this tool, anonymized data were automatically transferred from the Electronic Health 
Records (EHR) towards the Clinical Data Management System (CDMS). This enhanced 
clinical trials conduction on chronic viral infections. 
A project about clinical data re-use applied to tuberculosis management was developed too, 
to consider a different approach to infectious diseases. Indeed, tuberculosis is not chronical 
but could have relapses if not properly treated [75] [76]. The platform allows TB patients’ 
surveillance by tracking their transfers to other hospitals or outpatient departments: a 
complete surveillance could be reached with a total adherence of hospitals to the network. 
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4.2 Second layer: Clinical trials automatic feed 
The huge amount of data collected can be re-used to perform multi-centric clinical trials. 
The former architecture already allowed to perform regional clinical trials. Clinical studies 
are very important to conduct focused surveys, especially in chronic diseases management. 
Several clinical studies have been conducted with the support of the LHN; initially data 
entry was manually executed, but the last clinical trials performed benefit from the 
automatic data sharing.  
Presently nine regional studies are supported by the platform [77] [78] [79] [80] [81] [82] 
as they are listed in table 4.2. They are all observational studies, except for AIFA HCV, 
which is a phase 4 study about new HCV drugs pharmacovigilance funded by Italian 
Medicines Agency (AIFA) in which Liguria is the pilot region. 
Each study has a specific interface and role based access control, but they share the same 
database in order to re-use the clinical information and avoid multiple data input.  
Studies Description Patients Centers involved 
MARHIV Study on Maraviroc therapy 120 8 
Long-Term Study on HIV long term non-progressor patients 35 2 
ACTeA-I Analysis of the costs for patients in antiretroviral therapy 208 4 
Vertical transmission Study on mother-to-child transmission of HIV 51 2 
IANUA Study on antiretroviral prescription appropriateness in HIV 2245 4 
T reg 
Determination of regulatory T lymphocytes as a new 
biomarker for HIV monitoring 
93 5 
VELA 
Effectiveness and sustainability strategies in the 
management of long-term HIV patient quality of life 
275 6 
AIFA HCV 
AIFA pharmacovigilance project for HCV therapy 
prescription in mono-infected and co-infected patients 
1504 8 
SCUDI Study on therapeutic failure in HIV patients 389 2 
Table 4.2: Clinical trials available on the LHN 
Other professional figures has been involved in the conduction of clinical trials and 
periodical meetings were organized with physicians, economists and psychologists. For 
example, in IANUA study the overall annual economic expense in Liguria region for HIV+ 
patient management and the related improvement in patients’ health were compared. 
Economists were employed for the cost effectiveness analysis and psychologists were 
designated to collect data related to patients perceived health status as marker of clinical 
quality. 
Another example of a regional study conducted on the platform is VELA (Valore Esiti 
Liguri per l’Appropriatezza della terapie HIV), whose main objective is the evaluation of 
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the appropriateness of HIV therapy prescribed in the Ligurian centers of infectious diseases 
during 2015 and 2016 according to guidelines.  
In an ever-evolving scenario like that of HIV infection, characterized by long-term therapy 
and burdened with multiple comorbidities, it is increasingly important an optimal 
prescription of the HAART therapies. Optimization in this case means having the 
opportunity to offer everyone the best pharmacological combination for his or her clinical 
situation. The first therapeutic lines are decisive in this context, as they are responsible for 
immune-virological success as well as possible side effects.  
In HIV treatment, the therapy is a crucial point: the currently available anti-HIV drugs 
cannot completely cure HIV, but treatment with a combination of these drugs can reduce 
the amount of the viral load and prevent the virus from reproducing. This allows the 
immune system to fight off infections and other illnesses, granting an almost normal life. 
There are currently more than 20 approved antiretroviral drugs; taking two or more 
antiretroviral drugs at a time is called combination therapy. The way to choose which drugs 
to be combined is highly difficult and it depends on many factors. The efficacy of HAART 
treatment is reached only with a complete adherence of the patient at the therapy prescribed, 
otherwise drug resistances arise. At the beginning of the treatment, the combination of 
drugs that a person is given is the first line therapy. If HIV becomes resistant to this 
combination, or if side effects are particularly bad, then a change to second line therapy is 
usually recommended; higher the current line, less the probability of next therapeutic 
success. Thus the adherence is a key factor in avoiding treatment failure, and the concept 
of retention in care assumes great importance. In figure 4.5 shows VELA main page 
interface. 
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Figure 4.5: An example of the web interface showing the main page of VELA study with the principal 
information 
Even if the clinical trials implemented have different purposes and procedures, their 
belonging to a single platform allows to integrate common information among trials. In 
this way, the clinical information that were recorded to monitor the follow up for a 
particular study can be available for other studies. Consequently, a patient can be involved 
in multiple trials simultaneously but clinical data have to be recorded only once. 
Appreciating the low effort in participating in these clinical trials, physicians of connected 
centers requested an extension of this mechanism to facilitate the participation to external 
trials too. In chronical infectious diseases field, as mentioned in the material section, many 
research databases collect data at national level. Solutions to fulfill this request have been 
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set up for ARCA and CISAI databases. A semi-automatic solution has been set to enable 
physicians to connect from CISAI web site to the network, asking for the data of interest, 
in a specific time interval. This solution is not fully automatable, due to intrinsic 
complications in the trial structure that requires human supervision. The connection with 
ARCA database, that was developed within a master degree thesis under my supervision, 
enables a complete automatic and bidirectional data exchange between the two platforms 
(but on a limited number of parameters). 
In both cases, the first step was an initial matching of the anonymous codes used by the 
two systems to identify patients. The second step consisted in a manual matching of the 
clinical parameters involved in both sites, which do not employ terminology standards, and 
their translation into standard LOINC codes according to their meaning, measurement units 
and properties. 
An intermediate solution was adopted for ICONA database, because the system 
administrators did not allow access to the database structure. To feed ICONA database 
without data manual copy, Excel files containing the information of interest of the patients 
involved are presently downloaded from the network and reloaded into ICONA database 
by their technicians. A fully automated system will be set up when bureaucratic constraints 
will permit it. 
At present, 1243 LHN patients are registered in the ARCA database, 590 in CISAI and 458 
in ICONA. A program has been developed to continuously update the ARCA database with 
CD4+, CD8+, CD3+, HIVRNA and genetic sequence data for all patients included in the 
LHN. The CISAI study also involves HCV infected subjects and collects a greater amount 
of data. 
The interchange of data at a national level ensures a wider vision that grants greater stability 
in statistical elaborations and knowledge inference.  
In chronic infectious diseases data management, where a significant amount of data is 
periodically collected and analyzed, this system assumes great importance. In this and other 
domains, all the collected data will provide wide and scientifically valid samples.  
To estimate the impact of the application of the platform developed in clinical practice, a 
fast anonymous questionnaire was set. It was developed as an indicator of progress, stalling 
or failure, and it could give an evaluation of the improvement in the effort to merge clinical 
practice and medical research. The questionnaire is anonymous since only the user age, the 
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experience with the platform and the frequency of use are requested. Two different sets of 
questions were asked, depending on which scenario the user’s hospital belonged to. Two 
scenarios were depicted: the first one includes the hospitals that do not allow external 
agents to access data from LIS (that insert data into the LHN only manually through the 
web interface). The second scenario includes the hospitals that are automatically connected 
to the LHN architecture (San Martino, Galliera and Sanremo). In the first scenario case, a 
few questions are addressed to investigate if the user perceives differences with the use of 
paper-based case report forms, and if he thinks that the adoption of the second scenario 
would improve his way of working. To automated system users, questions are focused on 
evaluating the level of satisfaction in terms of time and quality. Moreover, in this second 
scenario users should indicate if they appreciate less workload in the participation to 
regional and national studies thanks to the automatic support. In both cases, at the end of 
the questionnaire, users had to specify if they would like to integrate a decision support 
system to the platform and if they would suggest the adoption of the platform to their 
colleagues. The questions can have numeric answers on a scale 0 to 5. 
Sixteen questionnaires were collected at the end of 2015, 5 in the first scenario and 11 in 
the second. The user’s average age was 37 with a standard deviation of 11. All 16 users 
(100%) asserted that they would recommend adoption of the platform to their colleagues 
and 14 (88%) appreciated the idea of integrating a decision support system. The questions 
and the results of the questionnaires are summarized in table 4.3. 
 
Average values 
Questions (on a scale of 0 to 5, with 0 being poor and 5 being excellent) I scenario II scenario 
Weighted 
average 
How much did the platform improve data input in respect to paper-based 
collection? 
4,4 4,1 4,2 
How much did the platform simplify clinical trials conduction? 4,2 3,4 3,6 
To what extent do you think the automatic import of LIS data has 
lightened the workload and reduced the time spent entering data 
manually? 
- 4,7 4,7 
To what extent do you think the automatic import of LIS data has 
facilitated the export process towards national databases? 
- 4,4 4,4 
To what extent do you think the automatic import of LIS data has 
improved the quality of the data collected? 
- 4,0 4,0 
To what extent do you think the automatic import of LIS data could 
lighten the workload? 
4,8  4,8 
Weighted average 4,4 4,1 4,2 
Table 4.3: Questions asserting the satisfaction level of the platform, with numeric answers on a scale 0 to 5 
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4.3 Third layer: CDSS 
The flexibility and the capability to continuously evolve is the key points of the structure, 
in order to follow the typical LHS cycle, which consists on learning from data and applying 
knowledge to clinical practice. The evidence abstracted by clinical trials results, integrated 
with existing guidelines, can be used as the knowledge base for a clinical decision support 
system. 
A fundamental feature that arouses from literature is that CDSS, to be truly efficient, should 
be smoothly integrated within the clinical information system, interacting with other 
components, in particular with the electronic health record. Since data stored in EHR are 
of heterogeneous nature, differing in the data models, schemas and semantic, there is the 
need of standardized solutions. The choice of joining the HeD initiative instead of using 
other cited standards for CDSS is driven by the already existing platform, which involves 
other HSSP specifications, as already described. 
To fully comprehend theoretical in-depth analysis, I considered a useful attitude to have a 
more practical approach to the matter in parallel of literature researches. I searched for a 
restricted field in which apply an initial draft of CDSS and, during a meeting with infectious 
diseases physicians, the whole team agreed to implement decision support to HIV-infected 
patients drug prescription. In HIV treatment, the therapy is a crucial point: the currently 
available anti-HIV drugs cannot completely cure HIV, but treatment with a combination of 
these drugs (called HAART – Highly Active AntiRetroviral Therapy) can reduce the 
amount of the viral load and prevent the virus from reproducing. This allows the immune 
system to fight off infections and other illnesses, granting an almost normal life. There are 
currently more than 20 approved antiretroviral drugs, subdivided into four main classes: 
NRTI (Nucleoside reverse transcriptase inhibitors), NNRTI (Non-nucleoside reverse 
transcriptase inhibitors), PI (Protease inhibitors), and II (Integrase inhibitors); taking two 
or more antiretroviral drugs at a time is called combination therapy. The way to choose 
which drugs to be combined is highly difficult and it depends on many factors. The efficacy 
of HAART treatment is reached only with a complete adherence of the patient at the 
therapy prescribed, otherwise drug resistance arises. At the beginning of treatment, the 
combination of drugs that a person is given is the first line therapy. If HIV becomes 
resistant to this combination, or if side effects are particularly bad, then a change to second 
line therapy is usually recommended; higher the current line, less the probability of next 
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therapeutic success.  Thus the adherence is a key factor in avoiding treatment failure, and 
the concept of retention in care assumes great importance [6]. Therefore, CDSS would be 
very useful in HAART prescription, with the aim not to substitute the physician with a 
computerized tool, but to aid him by providing patients’ historical data on adherence, 
prescription, resistances acquired and comorbidities. 
The first step to the development of this tool was to collect data about therapies and 
integrate it in the current architecture, using the Italian AIC standard codes for drugs and 
the international ATC codes to identify active ingredients. HAART drug sale is not allowed 
in pharmacies, so patients withdraw their drugs in the hospital every month. The register 
of patients’ ambulatory withdraws in excel format was the first way we accessed data. In 
the last few months, a direct network towards San Martino hospital drug management 
system has been performed, thanks to the collaboration with the appointed company 
Ingegneria Biomedica Santa Lucia S.p.A. 
The second step consisted in the consideration of existing clinical guidelines regarding 
HAART therapy prescription and the standardization of the related control-flow engine 
using the GLIF model. The GLIFeditor developed by Medical Objects has been used to 
draw the logical flux that describes the “BHIVA guidelines for the treatment of HIV-1-
positive adults with antiretroviral therapy 2015” of the British HIV Association [83]. This 
guideline, together with the national “Linee guida italiane sull’utilizzo dei farmaci 
antiretrovirali e sulla gestione diagnostica-clinica delle persone con infezione da HIV1” 
[84] has been used in VELA project. VELA (Valore Esiti Liguri per l’Appropriatezza della 
terapie HIV) is one of the regional studies conducted on the platform, whose main objective 
is the evaluation of the appropriateness of HIV therapy prescribed in the Ligurian centers 
of infectious diseases during 2015 and 2016, according to guidelines. Using GLIF editor, 
patients’ states, decisions, actions and the related links were descripted in a computer 
interpretable way. To embed automatic decision steps, scripts in GELLO language has been 
used, to query archetype data. 
After the learning phase, the implementation of a CDSS through which apply the 
knowledge to clinical practice has been performed exploiting the standards described by 
HeD Initiative. 
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4.3.1 Clinical guideline representation 
The initial idea was to create a computer interpretable code to describe the workflow of 
clinical guideline and integrate it into a custom informatics program. GLIF was chosen as 
guideline representation format mainly because it is based on HL7’s Reference Information 
Model (RIM). GLIF editor provides a user-friendly interface to describe clinical guideline 
through a flow chart. The blocks of the flow chart represents different classes of the GLIF 
model. The first implementation of this tool was to describe the part of clinical guideline 
“BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 
2015” that is related to therapy prescription for naïve patients, that are patients that are new 
to this kind of therapy. I decided first to concentrate on this restricted group of subject, 
mostly because VELA project involves this kind of people. Moreover, the management of 
patients who have already undergone HAART therapy is more complicated, because also 
possible resistances to some active ingredients previously swallowed need to be taken into 
consideration. In figure 4.6 six different sub-guidelines organized into different layers are 
represented. The starting layer is the one describing the patient state. Action steps are 
represented using green rectangles. From the action step “Naïve” the arrow brings to the 
second layer, which considers two sub-guidelines embedded into two corresponding action 
steps, concerning the starting time and the kind of drugs to start. The first sub-guideline 
considers clinical parameters of the patients to evaluate the urgency of starting HAART. 
The second leads to a third layer in which the details about the kind of therapy are exploited. 
According to the guideline, a naïve patient has to take a therapy composed by two NRTI 
agents and a third agent from another class. In this third layer, two different sub-guidelines 
are dedicated to the choice of the three active ingredients that most suits the patient’s 
clinical profile. 
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Figure 4.6: Definition of BHIVA clinical guidelines on HAART prescription in naive patients developed 
with GLIF Editor of Medical Objects 
The decision steps are represented as pink or blue rhombuses. GLIF Editor can be used as 
an execution engine too, to test if the logic data flux described by the flux diagram is 
correct. A decision choice can be expressed manually by the user in testing phase, or it can 
be derived automatically by the editor basing on patient’s data. In the first case the rhombus 
is pink, in the second one it is blue. To automatize a decision block, a code in GELLO 
language expressing the choice logic should be integrated. During the running phase, the 
GELLO code evaluates this logic against patient’s data that can be loaded inside GLIF 
Editor. Patient’s data can be loaded in standard HL7 v2 format. To test the diagrams 
created, instructions in GELLO language have been embedded into some decision blocks. 
For example, in figure 4.7 there are two blue decision blocks that leads to different paths 
of the diagram to suggest a list of drugs suitable for the patient. The first one evaluates if 
the last available value of creatinine clearance is less than 70 mL/min. If the answer is no, 
the second block evaluates if the baseline viral load is less than 100000 copies/mL. In figure 
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4.8 the GELLO code for the evaluation of the first block is reported. In the second line of 
this GELLO code, a variable that describes the entity “creatinine clearance” is declared. 
The type of this variable is CD (Coded Value) that is a type derived from the RIM 
(Reference Information Model) model of HL7 that has been imported (figure 4.9). The 
coded value 2163-4 is the standard LOINC code for the entity creatinine clearance, as it is 
appreciable from screenshot in figure 4.10. In the following instruction, the program 
searches for this code among the patient’s data imported, sorted by time to take the last 
available value. After, it compares the value found with the threshold to provide the final 
answer that will drive the flux towards one of the two available options (Yes/No). This 
answer is expressed according to the type GLIFDecisionResult of GLIF entity class model 
that was imported too. 
To test this program inside GLIF Editor, I imported a hand-written example of HL7 v2 
message (figure 4.11) that contains some clinical observations of a fake patient. In 
particular, in this message, the creatinine clearance assumes value 80 mL/min. While 
executing the test, after loading patient’s data, the results and the values assumed by the 
variables involved are shown by the editor (figure 4.8). In this case, the final answer 
correctly assumes false value. Similarly, the second decision block was realized with 
GELLO code inside, and tested against the patient’s data imported. In the same HL7 v2 
message, HIVRNA assumes value 100 copies/mL, so in this case the final answer should 
be yes. Figure 4.12 shows the final execution of this sub-guideline, highlighting the 
effective data flow that occurs, which is the one expected. 
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Figure 4.7: GLIF Editor blocks to define the third agent of HAART therapy with GELLO code embedded 
to automatize the two decisions steps execution. 
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Figure 4.8: GELLO code execution in GLIF decision node. The GELLO code related to the first decision 
step evaluates if the last value of creatinine clearance of the patient considered is lower than the set 
threshold (70 mL/min). LOINC code is used to identify the parameter. 
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Figure 4.9: Brief overview of the object oriented models imported. 
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Figure 4.10: Creatinine renal clearance parameter definition in LOINC code 
 
Figure 4.11: HL7 v2 message used to test the GELLO code execution in GLIF decision node. The 
creatinine clearance value measured is 80 mL/min, which is greater than the threshold set in the decision 
node. 
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Figure 4.12: Automatic execution results. The HL7 v2 message in figure 4.11 was uploaded in GLIF Editor 
and the created algorithm evaluates the GELLO code against patient’s data read in the HL7 v2 message. 
The editor translates the flow chart edited by the user into a hidden code in XML standard 
language. As mentioned above, the initial idea was to create a computer interpretable code 
to describe the workflow of clinical guidelines and integrate it into a custom informatics 
program. In this way, that program should be able to evaluate flow chart decision steps 
against patients’ data, providing a custom interface to physicians. For this reason, I tried to 
re-use the created XML, but I came across some difficulties in embedding this code into a 
software program. (figure 4.13) 
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Figure 4.13: XML representation of the block diagram developed with GLIF Editor. 
4.3.2 Knowledge Modules 
After representing the acquired knowledge using GLIF, in order to use this knowledge as 
the basis of the decision support system, I developed a database structure suitable to store 
it and to make it available to a computer program. Each “package” in which knowledge is 
stored is called “Knowledge Module” (KM). Maintenance and versioning of knowledge 
modules are very important and should be considered in database development. The 
database structure should be very flexible in order to easily allow the management of 
knowledge modules changing according to new versions of the guidelines involved and 
new literature publications. A flexible structure should consider normalization. To 
reproduce the GLIF flux diagram logic, I assumed that each KM should have an ordered 
collection of criteria that have to be evaluated according to a specific comparison operator. 
The diagram of the database developed is shown in figure 4.14. Table 
“Combo_Evaluations” contains the list of criteria that are to be evaluated for each KM. 
Criteria are expressed through standard vocabularies codes, such as LOINC for clinical 
parameters, ICD9 for diagnosis and ATC for the active ingredients of drugs. Evaluations 
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for each criteria in KM will be done using comparison operators that are defined into table 
“Comparison_Operators”. In case of  two-way operators, the comparison value is specified 
in column “Comparison_Value” of table “Evaluation”. The list in “Combo_Evaluations” 
is not ordered; this table only contains reference to which is the first evaluation of a KM. 
In fact, the chain is not fixed, but has to be dynamically created, according to the 
evaluations results, as in a flux diagram. The order of the evaluations is therefore defined 
into table “Results_Combo_Evaluation”. In this table, each comparison is related to the 
two possible answers (0 or 1) and to the related next step, that is the id of the table 
“Combo_Evaluations”. With this logic, the path to follow is dynamically drawn according 
to evaluations results and ends when the next step id is null. The implementation choice 
was to consider the possibility of providing guidance not only at the end of the path, but 
also gradually at each step. This could be specified in table “Combo_Criteria_Tip”, in 
which from 0 to N tips can be provided at each step (that is for each row of the table 
“Results_Combo_Evaluation”). The system is capable of dealing with generic advices, 
such as pharmacological prescriptions, diagnostic procedures, blood test recommendations 
etcetera. Each advice is associated with a weight that indicates the level of strength 
established by the guideline for the action proposed. In the program code, during the 
execution of the recursive function that iteratively evaluates the criteria for the involved 
KM, all the advices suggested at each step are recorded into a list. At the end of this 
function, this list is checked. Discordant tips are analyzed and the one with the lowest 
weight is taken into consideration. 
80 
 
 
Figure 4.14: Knowledge Modules Database structure 
The strength of this structure is that it is flexible and easily adaptable to different contexts 
and guidelines. The guidelines stored in such a database are prone to updating, since only 
the records in the tables have to be changed, while the structure of the database and the 
program code do not need to be modified. This generic and adjustable structure has been 
tested in the use case reported below. 
4.3.3 Decision support service 
The database structure described stores the knowledge modules that will be used by the 
decision support system as knowledge base. The decision support service has been 
developed according to the HL7 version 3 standard Decision Support Service (DSS) 
Release 1 (August 2011). The decision support service utilizes patients’ data for the 
execution of the evaluation logic that is contained into the knowledge modules. The DSS 
service has to be used by a DSS client that is an external entity that interacts with the DSS 
to obtain its services. The client, querying the DSS service, has to specify the KM to be 
used in the evaluation phase, and has to provide patient’s data. The DSS service returns 
inferences regarding the patient in a pre-defined format. A general schema describing the 
actors involved in the decision support is shown in figure 4.15. 
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Figure 4.15: General schema describing the actors involved in the decision support 
The primary functionality of a DSS service is to receive patient’s data as input and returns 
patient specific conclusions as output. For both input and output, the HeD group suggests 
the use of the HL7 Virtual Medical Record (vMR). The aim of the designed system is to 
develop the service using a standard structure, so that an ad-hoc client can be built for each 
healthcare facility that wants to connect to the service. In this way, the interoperability 
problems described in the previous chapters that could limit the adoption of decision 
support tools are resolved. This architecture allows existing resources to be more readily 
re-used, as the main system does not have to be modified each time a new institution join 
the system. Moreover, since the DSS uses a standard interface, client implementers would 
be able to leverage CDS content from different DSSs in an easy manner. The normative 
specifications defined in the implementation guide [72] consist of two functional profiles: 
the HSSP Simple Evaluation DSS Functional Profile and the HSSP Complete DSS 
Functional Profile. Figure 3.18 provides a view of the operations supported by the two 
functional profiles. The conformance with the HSSP Simple Evaluation DSS Functional 
Profile version 1.0 is granted with the implementation and support of the service operation 
“evaluate” of the Evaluation interface. The evaluate operation evaluates one or more 
knowledge modules using the data provided as EvaluationRequest object and returns the 
results of the evaluation as an EvaluationResponse object. To describe the service interface, 
a common language exists: the Web Service Definition Language. WSDL documents have 
an associated XSD (XML Schema Definition) that describes the static structure of the 
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complex data types being exchanged by the service methods. A WSDL document and the 
associated XSD are provided by HL7 with the specification of the DSS. To develop a WCF 
web service starting from the WSDL I used WSCF.blue tool. This approach is named 
schema-based contract-first design and it is schematized in figure 4.16. 
 
Figure 4.16: Schema of WSCF.blue schema-based contract-first design 
WSCF.blue provides a user interface to define the options to create the classes’ code, both 
client and service side (shown in figure 4.17). 
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Figure 4.17: WSCF.blue user interface to define the options to create class code, both client and service 
side 
The Platform Specific Model content of the specification includes three WSDLs: one is the 
“dssBaseComponents.wsdl” that defines the type and the message elements that are shared 
by the two functional profiles; the others are “dssEvaluate.wsdl” and “dss.wsdl” that 
contain the portType, binding and service elements of the simple evaluation and the 
complete functional profiles respectively. To develop a web service compliant to the simple 
evaluation profile, I blended the “dssBaseComponents.wsdl” with the “dssEvaluate.wsdl” 
in a single file. 
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The first attempt to generate code with WSCF.blue tool from the created file failed, because 
the first part of the WSDL provided was not correct. Some <part> parameters of different 
messages had the same name. After correction by renaming these parameters, the tool 
worked properly. Abother problem faced with WSCF.blue tool is that it is not compliant 
with Visual Studio versions after 2013. To use this tool, Visual Studio 2012 was installed 
on a virtual machine. The code for both client and service sides has been generated. The 
main classes generated from the XSD files has been collected into a library called DSS.dll. 
This library was enclosed into both the service and the client projects. The interface 
developed is standard, and the WSDL is available for any institution that would like to 
build a client to connect to the service. Instead, the implementation of the service function 
“evaluate” is customizable. I developed this function according to the content of the 
knowledge database described in the previous paragraph. The input of the function is a 
standard “evaluate” element. In this element, the KMs (at least one) to be used and the 
patient’s data needed for the evaluation are specified. The program first checks if the KMs 
specified are actually stored into the database (checking by BusinessId and version).  
The patient’s data are stored into the semantic payload of the element “evaluate” (exactly 
into <evaluate><evaluationRequest><dataRequirementItemData><data> 
<base64encodedPayload>). 
The payload for the request is the clinical and contextual data that is evaluated by the DSS. 
The payload for the response is the guidance, such as for clinical interventions, provided 
by the DSS. The implementation guide affirms that vMR format shall be used as request 
payload, and one of the following shall be used as response payload: vMR, data type, string 
name-value pairs or Action Group. I decided to use vMR for both request and response 
payload. 
The service receives and interprets the vMR, and checks if all data requested by the selected 
KM have been provided. If so, the recursive function described in the previous paragraph 
is called to evaluate the KM against patient’s data. The evaluation is then encapsulated as 
vMR into the payload of the standard element “evaluationResponse” and it is returned as 
the output of the evaluate function. 
After implementing the service, I developed an ad hoc client for the Ligurian HIV Network 
users to test the system. The client shows a user friendly interface integrated on the Ligurian 
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HIV Network web site. The client application collects the clinical data of a patient selected 
by the clinician and calls the evaluate service function, specifying also a specific set of 
KMs available in the database. To test the system and to examine the SOAP messages 
exchanged between the client and the service, a tracing system was set. The 
XmlWriterTraceListener class from the library “System.Diagnostics” has been used to 
convert tracing and debugging information into an XML-encoded text stream. The Service 
Trace Viewer Tool (SvcTraceViewer.exe) has been used to display the XML output. An 
example of SOAP message traced by this tool during a service call operated by the 
developed client application is reported in figure 4.18. The body of the SOAP message 
reports the evaluate element, which points out to the namespace of the standard DSS 
specifications. The element <kmEvaluationRequest> contains the list of KMs that the client 
wants to use. In this view, the semantic payload is collapsed. In the next paragraph a 
specific example of the implementation of a specific set of KMs will be presented. 
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Figure 4.18: An example of SOAP message traced by the tool during a service call operated by the client 
application 
4.3.4 Specific implementation of DSS client to evaluate 
HAART therapy prescription in naive patients 
Exploiting the GLIF representation of the BHIVA guidelines on HAART prescription, I 
developed a HAART prescription support service for naïve patients. The first 
implementation only regards naïve patients because it is easier to manage patients that 
never had therapy failure and have never developed drug resistances. The structure of the 
system developed is generic and highly reusable for different purposes, so further additions 
are very easily manageable. It is not necessary for the service to be changed, thanks to the 
use of standard interfaces and standard format for both input and output. The database 
structure remains unchanged too. To add a new KM, it only takes to add new lines to 
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specific tables of the database. The client application is the only piece that changes, because 
it is the conjunction ring between the standard service and the custom hospital database. 
The BHIVA guidelines suggest that a naïve patient has to take a therapy based on two 
NRTI class active ingredients and one INI or NNRTI or PI class active ingredient. Two 
different KMs have been developed to independently manage the two NRTI class active 
ingredient selection and the third one. In figure 4.19, a sketch of an intermediate passage 
using Excel towards the translation from GLIF to the database content is reported. The 
database logic has been explained in the previous paragraph. According to it, different 
criteria evaluation steps are recorded into the intermediate table shown in figure, each with 
the related output (the drug active ingredient suggested) and weight. According to the 
guidelines, four weights from -2 to +2 excluding 0 have been set to indicate respectively: 
-2: avoid this drug 
-1: be careful 
1: acceptable alternative 
2: recommended 
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Figure 4.19: Part of the guideline rules explicitation for KM database table immission 
The next step was the insertion of this knowledge into the corresponding tables of the 
database. The normalized structure of the database avoids row fields’ repetitions that are 
visible in the Excel file.  
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Figure 4.20: Schema of the communication between the main actors involved in the CDSS execution 
To test the knowledge module created, I built a client embedded into the Ligurian HIV 
Network to support physicians of San Martino hospital in prescribing a new therapy to 
patients. A similar client application could be done also for Galliera and Sanremo hospitals, 
which have automatic connection to LIS, to retrieve data that are not available on the 
Ligurian HIV Network. The interface is simple and user friendly, as it is appreciable from 
figures 4.21, 4.22, 4.23. With the first screen of the program, the physician can choose the 
patient to be evaluated. 
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Figure 4.21: Ligurian HIV Network web interface that provides HAART prescription support for a specific 
patient. Patient selection and anagraphic data display 
There is also the possibility to call the prescription support from inside a patient section. In 
both cases, the next screen provides the list of all NRTI active ingredients colored 
according to the prescription support. Figure 4.22 displays the interface with the color 
legend. Selecting two of the proposed NRTIs it is possible to access to the second 
evaluation, according to the second KM created, to evaluate the third agent (figure 4.23). 
The next page displays the remaining active ingredients divided per class, colored 
according to the DSS guidance. Selecting the third agent, a text shows a summarization of 
the therapy selected and a comment about the appropriateness according to the selected 
patient’s data. 
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Figure 4.22: Ligurian HIV Network web interface that provides HAART prescription support for a specific 
patient. NRTIs choice with standard DSS guidance expressed with colors. The system provides an 
extremely user-friendly interface that conceals the complexity behind the system. 
92 
 
 
Figure 4.23: Ligurian HIV Network web interface that provides HAART prescription support for a specific 
patient. Third agent choice with standard DSS guidance expressed with colors. In the recap of the selected 
therapy, advices about the selected drugs are displayed. 
The interface is very simple and user friendly and masks the complexity behind the system. 
The actors implied and the related list of calls among them is represented in the UML 
diagram in figure 4.24. 
 
Figure 4.24: UML sequence diagram representing the data exchange among the users involved in the 
decision support process 
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The client is embedded into the Ligurian HIV Network web interface. The physician 
addresses the client to receive prescription support for a specific patient. The client asks 
for patient’s data to the Ligurian HIV Network database. Then, the client checks if all the 
patient’s data needed by the knowledge module has been provided by the LHN database, 
and if the answer is negative, another call to the San Martino hospital database is performed 
to retrieve all data. With this data, the client can create the vMR document that will be 
encapsulated into the evaluate object together with the KM to be used; this will be used as 
the input when calling the evaluate service function. The service elaborates the information 
received, evaluates it and returns an evaluationResponse object with the decision support 
information, which is the list of drug active ingredients suggested and the related weights. 
In order to codify the guidance on the most appropriate list of drug active ingredients, the 
response vMR extends the attribute element for the entity ClinicalStatement as 
SubstanceAdministrationProposal using the template vMR Extended Type according to 
“HL7 Virtual Medical Record for Clinical Decision Support (vMR-CDS) Templates, 
Release 1”. The template code identifier has root 2.16.840.1.113883.3.1829.11.14.8.7 and 
name “attribute”. The complete parameters are listed in table 4.4, with the possible values 
used to represent the list of drug active ingredients considered and the related weights in 
table 4.5. 
NRTI active drugs are evaluated in couples (combination of two). To represent this 
concept, the relatedEntity of the substance entity is used.  
The response vMR is re-elaborated by the client to provide user friendly support to the 
physician. 
The sample scenario created to support HAART prescription was set up at the end of 2016, 
and it was thoroughly tested in the following months. After about a year of usage, this 
system should have positively affected the antiretroviral prescriptions to Ligurian HIV+ 
naïve patients in 2017. To evaluate its real impact on clinical care, it was necessary to find 
a way to measure the improvements in the quality of life, in the prescription appropriateness 
and in therapy adherence. 
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Figure 4.25: substanceAdministration class diagram 
Data 
Element 
Name 
vMR Data 
Element 
Cardi
nality 
Manda
tory 
Confor
mance 
Fixed 
Value 
vMR Data Type Constraints 
Template ID templateId 1..1 Y R Y CodedIdentifier 
root SHALL be 
2.16.840.1.113883.3.1829.11.14.8.7 
identifier name SHALL be 
"Attribute" 
Name of 
Concept 
name 1..1 Y R  ST 
This token represents the name of the 
extension attribute 
Concept 
Semantic 
Code 
semanticCode 0..1 N   CD 
The code SHALL represent a 
concept from a managed terminology 
Value of 
Concept 
value 1..1 Y R  
ExtendedVmrTy
peBase 
The value SHALL be expressed 
using either a datatype that extends 
ANY, or using any 
ExtendedVmrType 
Table 4.4: Schema of the vMR Extended Type template defined into HL7 Virtual Medical Record for 
Clinical Decision Support (vMR-CDS) Templates, Release 1 
Name Value 
-2 Avoid 
-1 Caution 
1 Acceptable alternative 
2 Recommended 
Table 4.5: List of all the possible values used to recommend or avoid the drug active ingredients considered 
and the related weights 
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4.3.4.1 Quality of life improvement 
To give an objective measurement of the quality of life, I referred to the last results 
evidenced in IANUA study [78]. According to this study, the values of Lymphocytes T 
CD4 and viral load (HIVRNA) parameters can be optimal predictors of the quality of life 
of HIV infected patients. Lymphocytes T CD4 are positively correlated with quality of life, 
while HIVRNA is inversely correlated. Appendix A1 shows two tables with CD4 and 
HIVRNA values in the last three years for patients that started antiretroviral therapy from 
2015 to 2017. To assess if the quality of life of the patients considered had increased after 
the setup of the HAART prescription support tool, values of the two-year period 2016/2017 
were considered, in order to evaluate if significant differences were registered between 
2016 and 2017. Moreover, if the results highlighted a significant improvement from 2016 
to 2017, I thought it would be interesting to prove that no significant improvement is 
registered in the period before 2016, to demonstrate that the improvement has to be 
attributed to the system developed. 
Data registered reveal that from 2015 to 2016 there is no significant improvement both in 
HIVRNA and CD4 values, as we considered an interval of confidence of 99%. From 2016 
to 2017 there is a highly significant drop of HIVRNA values (p=4.2 ∙ 10−4) and a 
significant increase of CD4 values (p=5.8 ∙ 10−3). 
4.3.4.2 HAART prescription appropriateness improvement 
Prescription appropriateness on such a large sample of patients can be assessed through a 
score system based on the Italian guidelines. Specifically, the system attributes to each 
HAART regimen a score that combines the recommendation suggested by the Italian 
guidelines and the relative monthly costs. The most appropriate and cheaper therapeutic 
regimens get a maximum score of 1.00, while the other regimens are assigned a 
decrementing score based on the two parameters above (range: 0.001-1). The score system 
was used in VELA study and it demonstrated to be an effective tool for monitoring the 
correlation of treatment appropriateness, drug expense and clinical outcomes [85]. Overall 
appropriateness score was calculated for therapy prescribed in 2015 and in 2016 to naïve 
patients and its results were respectively 0.60 and 0.75. The Student’s T test reveals that 
the prescription appropriateness improvement that was registered was statistically 
significant (p=1.7 ∙ 10−4). Monthly therapy mean cost in 2015 was € 919.60 ± 247.19. In 
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2016 the average monthly cost was significantly decreased to € 816.18 ± 150.42 
(p=1.4 ∙ 10−4). Complete data are reported in appendix A3. 
4.3.4.3 Therapy adherence improvement 
Therapy adherence monitoring is assisted by a system that is currently under refinement, 
which automatically retrieves data from San Martino hospital’s therapy dispense system. 
This system deals with both ambulatory delivery and unit dose management (the robotized 
system of drug administration to hospitalized patients). Adherence is calculated according 
to the formula below (1): 
𝐴𝑑ℎ𝑒𝑟𝑒𝑛𝑐𝑒 =
1
#𝑟𝑒𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒
#𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑑𝑜𝑠𝑒𝑠+#𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑑𝑜𝑠𝑒𝑠
∆𝑑𝑎𝑦𝑠
   (1) 
where: 
 #recurrence is the number of doses that the patient has to take daily 
 #delivered doses is the number of doses that the pharmacy delivered to the patient 
 #remaining doses is the number of remaining doses if the drug was, as desirable, 
retired before the end of the cycle. 
 ∆days is the number of days between the date of delivery of the drug and the 
expected date of the end of the therapeutic cycle. 
Adherence calculated in this way can range from 0 to 1. The values of adherence were 
calculated on patients undergoing new therapy in the period 2015-2017. The table 
containing all the values is reported in appendix A2. A significant improvement was 
registered in therapy adherence from 2016 to 2017 (p=1.7 ∙ 10−5), while no significant 
difference is registered from 2015 to 2016. 
4.3.4.4 Timings monitoring 
Speed is a focal point in a system that provides decision support and it is highly recognized 
the importance of velocity optimization [86]. Timings have been accurately monitored 
during the testing phase of the HAART prescription support system developed. Timings of 
the two evaluation phases were measured. In the evaluation phase, the actions in table 4.6 
were considered: 
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Actor Action 
Client Patient’s data retrieve from the electronic data source (hospital EHR or 
CDMS) 
Client vMR construction with patient’s data and KMs 
Client vMR dispatch to the web service 
Web Service vMR validation 
Web Service Evaluation of the KMs according to the data contained into the vMR 
Web Service Response vMR construction with the evaluation results 
Web Service Response vMR dispatch to the client 
Client vMR validation 
Client Display of the evaluation results 
Table 4.6: List of all actions carried out by the client and the web service in the evaluation phase 
The client, the DSS service and the data sources are all on the same network, even if not 
on the same server machine. Therefore, the timing measured could be misrepresented. To 
assess the real capabilities of the system and to evaluate its actual efficiency, a proof of 
evidence with an external client was developed. This client with its fake patients’ data 
source were installed on a server within the university network, to simulate a call to the 
standard DSS web service by an external entity. The related timings were measured.  
In both cases, the timings were measured through the “Page load time” Google web 
extension, which measures page load time and displays it in the toolbar (figure 4.26). 
 
Figure 4.26: Timings measuring through the “Page load time” web extension of Google 
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The results of the timings measured are displayed in table 4.7. 
 Client in hospital server External client 
 Hospital network University network-hospital network 
 
First DSS 
evaluation 
response time (s) 
Second DSS 
evaluation 
response time (s) 
First DSS 
evaluation 
response time (s) 
Second DSS 
evaluation response 
time (s) 
09:00 0.33 0.44 0.48 0.53 
09:30 0.41 0.39 0.64 0.47 
10:00 0.38 0.37 0.61 0.45 
10:30 0.35 0.40 0.73 1.20 
11:00 0.37 0.41 0.68 0.45 
11:30 0.43 0.38 0.69 0.52 
12:00 0.35 0.41 0.78 0.47 
12:30 0.35 0.36 0.58 0.45 
14:30 0.36 0.41 0.64 0.46 
15:00 0.35 0.45 1.30 0.47 
15:30 0.36 0.49 0.73 0.51 
16:00 0.41 0.37 1.15 0.46 
16:30 0.35 0.40 0.52 0.50 
17:00 0.40 0.38 0.69 0.49 
17:30 0.35 0.41 0.48 0.47 
18:00 0.37 0.40 0.74 0.47 
Average 0.37 0.40 0.72 0.52 
Std dev 0.03 0.03 0.22 0.18 
Table 4.7: Timings measured in executing the list of all actions carried out by the client and the web service 
in the evaluation phase (crf table 4.6). The timings were measured in both the architecture configurations 
developed: for the client inside the hospital server (that is the case of the Ligurian HIV Network embedded 
HAART prescription support) and for an external client (that is the proof configuration created on the 
university server). Timings were monitored during all the day at different time intervals. 
The measuring were conducted in different moments of the day with scheduled intervals, 
in order to consider the variability within daytime. No significant difference was noticed 
among the intervals considered or between the two DSS evaluations (related to the two 
different KMs). A significant difference between the means of the two different 
architectural samples is registered with T Student Test (p value = 2.6 ∙ 10−6). In both cases, 
timings are very short with a mean value of 0.385 ± 0.035  seconds when all the architecture 
is inside the hospital server and 0.620 ± 0.221 seconds when an external client calls the 
DSS web service. 
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5 Discussion and conclusion 
The platform developed is an example of Learning Health System applied to chronical 
infectious disease field. Knowledge is generated from the data flowing from routine care, 
and it is fed back into the healthcare system to improve outcomes, through the decision 
support service implemented. The use of EHRs in both patient care and clinical research is 
a key element of the LHS vision and the standardization is necessary to inter-institutions 
data exchange.  
The already existing platform was enforced and widened, in order to make it the data base 
for the learning health system. User-free daily collection of clinical data from LIS was fine-
tuned. Three hospitals are actually involved in automatic data extraction: San Martino, 
Galliera and Sanremo hospitals. The automatic and daily updated flow of data have been 
enriched with microbiologic tests, antibiotic resistance tests to bacteria, serology data, 
immunization administration and therapy withdraws. After these extensions of the 
platform, the “Ligurian Vaccination in HIV Project” was developed in collaboration with 
the Department of Health Sciences (DiSSal) for the monitoring of vaccination coverage in 
HIV population [74]. 
A project about clinical data re-use applied to tuberculosis management has also been 
developed, to consider a different approach to infectious diseases [76]. Indeed, tuberculosis 
is not chronical but could have relapses if not properly treated. The platform allows TB 
patients’ surveillance by tracking their transfers to other hospitals or outpatient 
departments: a complete surveillance could be reached with a total adherence of hospitals 
to the network [75]. 
Continuous and close cooperation with physicians working in Ligurian infectious diseases 
wards was necessary to the development of the platform, since coordination and 
collaboration are essential features to achieve improvements in healthcare. Several 
meetings with the participation of other professional figures like psychologists and 
economists have periodically been organized, with the aim to create a multidisciplinary 
working group. Many clinical studies have been carried on within this team exploiting the 
developed platform; initially data entry was manually executed, but the last clinical trials 
performed benefit from the automatic data sharing. Appreciating the low effort in 
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participating in these clinical trials, physicians of connected centers requested an extension 
of this mechanism to facilitate the participation to external trials too. In chronical infectious 
diseases field, there are many research databases that collect data at national level [50] [51] 
[52]. Solutions to fulfill this request have been set up for ARCA and CISAI databases. A 
semi-automatic solution has been set to enable physicians to connect from CISAI web site 
to the network, asking for the data of interest, in a specific time interval. This solution is 
not fully automatable, due to intrinsic complications in the trial structure that requires 
human supervision. The connection with ARCA database enables a complete automatic 
and bidirectional data exchange between the two platforms, but on a limited number of 
parameters. In both cases, the first step was an initial matching of the anonymous codes 
used by the two systems to identify patients. The second step consisted in a manual 
matching of the clinical parameters involved in both sites and their translation into standard 
LOINC codes according to their meaning, measurement units and properties. To feed 
ICONA database without data manual copy, Excel files containing the interest information 
of patients involved are presently downloaded from the network and reloaded into ICONA 
database by their technicians. A fully automated system for this research database will be 
set up when bureaucratic constraints will permit it.  
Generally, clinical trials generate data on safety and efficacy of a medication or device. 
This knowledge used together with existing clinical guidelines, could form the basis for a 
decision support system. To express clinical guidelines in computable format, different 
standards exist. GLIF 3 (GuideLine Interchange Format) is a language for the structured 
representation of clinical guidelines. The GLIFeditor developed by Medical Objects has 
been used to draw the logical flux that describes the “BHIVA guidelines for the treatment 
of HIV-1-positive adults with antiretroviral therapy 2015” of the British HIV Association. 
This guideline, together with the national “Linee guida italiane sull’utilizzo dei farmaci 
antiretrovirali e sulla gestione diagnostic-clinica delle persone con infezione da HIV1” has 
been used in VELA project. VELA (Valore  Esiti Liguri per l’Appropriatezza della terapie 
HIV) is one of the regional studies conducted on the platform, whose main objective is the 
evaluation of the appropriateness of HIV therapy prescribed in the Ligurian centers of 
infectious diseases during 2015 and 2016 according to guidelines. Using GLIF editor, 
patients’ states, decisions, actions and the related links were descripted in a computer 
interpretable way. To embed automatic decision steps, scripts in GELLO language was 
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integrated, to query archetype data or data from vMR (virtual medical record). After 
representing the acquired knowledge using GLIF, in order to use this knowledge as the 
basis of the decision support system, I developed a database structure suitable to store it 
and to make it available to a computer program. The database has a flexible structure, 
thanks to normalization, in order to manage knowledge maintenance and versioning. This 
database is able to reproduce the GLIF flux diagram logic, assuming that each knowledge 
module (KM) should have an ordered collection of criteria that has to be evaluated 
according to a specific comparison operator. The decision support service was developed 
according to the HSSP standard Decision Support Service (DSS) Release 1. The decision 
support service utilizes patients’ data for the execution of the evaluation logic that is 
contained into the knowledge modules. The DSS service is called by a client, which 
specifies the knowledge modules to be used in the evaluation phase and provides patient’s 
data. The primary functionality of a DSS service is to receive patient’s data as input and to 
return patient specific conclusions as output. For both input and output, the HeD group 
suggests the use of the HL7 Virtual Medical Record (vMR). The normative specifications 
defined in the implementation guide consist of two functional profiles: the HSSP Simple 
Evaluation DSS Functional Profile and the HSSP Complete DSS Functional Profile. The 
service developed grants conformance with the HSSP Simple Evaluation DSS Functional 
Profile version 1.0. The evaluate operation evaluates one or more knowledge modules 
using the data provided and returns the results of the evaluation. To describe the service 
interface, a common language exists: the Web Service Definition Language (WSDL). 
WSDL documents have an associated XSD (XML Schema Definition) file that describes 
the static structure of the complex data types being exchanged by the service methods. A 
WSDL document and the associated XSD files are provided by HL7 with the specification 
of the DSS. I developed the WCF web service starting from the WSDL (the schema-based 
contract-first design approach) using WSCF.blue tool. To test the web service 
functionalities, I developed a web client application that creates a vMR document to wrap 
patient’s clinical data needed by the DSS service. The web service (WCF service) and the 
web client were realized using.NET framework 4.5 in Visual Basic language. To test these 
programs in a real scenario, with real data collected by the Ligurian HIV Network, I 
developed a HAART prescription support service for naïve patients exploiting the GLIF 
representation of the BHIVA guidelines on HAART prescription. The structure of the 
system developed is generic and highly reusable for different purposes, so further additions 
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are very easily manageable. It is not necessary for the service to be modified, thanks to the 
use of standard interfaces and standard format for both input and output. The database 
structure remains unchanged too. To add a new knowledge module, it only takes to add 
new lines to specific tables of the database. The client application is the only piece that 
changes, because it is the conjunction ring between the standard service and the custom 
hospital database. The flexible and standardized structure makes the network suitable to 
future extensions and the decision support system ready to new scenarios.  
The sample scenario created to support HAART prescription was thoroughly tested and the 
positive impact on clinical care was measured in terms of quality of life, prescription 
appropriateness and therapy adherence improvements. The benefits expected from the 
employment of the system developed were verified. Student’s T test was used to establish 
if significant differences were registered between the data collected before and after the 
introduction of the system developed. The results were extremely acceptable with the 
minimum p value in the order of 10−5 and the maximum in the order of 10−3. We can 
reasonably affirm that the improvements registered in the three analysis considered are 
ascribable to the system developed and not to other factors, because no significant 
differences were found in the period before its release. 
Speed is a focal point in a system that provides decision support and the importance of 
velocity optimization is highly recognized [86] [45]. Timings were monitored to evaluate 
the responsiveness of the system developed. We obtained extremely acceptable results, 
with the waiting times of the order of 10-1 seconds. 
The importance of the network developed has been widely recognized by the medical staff 
involved, as it is also assessed by a questionnaire they compiled to evaluate their level of 
satisfaction. From the questionnaires, a great level of satisfaction concerning the developed 
system arose. In particular, all the first scenario users agreed on the indisputable benefits 
that the adoption of the automatic system could provide on the workload. That condition is 
confirmed by the high grades given by the users belonging to the second scenario. 
During the implementation of this project, several difficulties were found and addressed. 
The high level of standardization allows the system to involve other healthcare facilities. 
The initial aim was to include all the infectious disease departments of Liguria region into 
the project, but we encountered bureaucratic difficulties. One persistent obstacle to the 
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transformation of existing systems into a linked LHS is the friction that may arise between 
researchers, healthcare providers, and health systems. Many health systems and individual 
hospitals are primarily configured to support the efficient provision of patient care, but are 
less accommodating to the presence of research activities within the same space. Thus, we 
encountered several difficulties in persuading hospitals’ HIS administrators and external 
clinical trials administrators to give us access to data, even with the ethical committee 
approval. Once tackled these challenges, bureaucratic timing slowed down the 
implementation phase. 
The system developed has few limitations that could be arranged in future developments. 
The CDSS client is only able to fill vMR documents with structured data, covering 
diagnosis, laboratory results and medication orders. Currently free text information cannot 
be processed. To overcome this limitation, natural language processing tools could be 
employed. Another limitation of the system developed is that the LHS cycle is not fully 
automated: a manual passage is required to insert the GLIF coded guidelines into the 
knowledge database. In future developments a tool that automatically validates GLIF code 
and embeds it into the knowledge database structure could be implemented, to bypass the 
manual insertion of a new knowledge module inside the platform. Few difficulties were 
identified in this process: a GELLO compiler is necessary to completely interpret the XML 
file with the GLIF guidelines. The GELLO code could be embedded into the XML file into 
a string type field, to describe the decision options. Another problem is that the 
“display_name” attribute of the “Decision_Option” tag is a free text field; it should be 
forced to a coded value to maintain the meaning of the objects within different institutions. 
Furthermore, the “Medical_Task” in the action tasks is a coded value, but the code system 
is not associated to an OID that univocally identifies it. Knowledge Artifact standard should 
be considered in the process of GLIF code integration into the knowledge database 
structure. 
Another future development should be the implementation of the HSSP Complete DSS 
Functional Profile, instead of the HSSP Simple Evaluation DSS Functional Profile to 
include the extended functionalities discussed in the “HSSP HL7 Decision Support Service 
(DSS)” paragraph.  
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Appendix A: results tables 
A1 Quality of life indicators 
A1.1 HIVRNA 
 Average HIVRNA value 
Patient ID 2015 2016 2017 
106 972 471 0 
107 630 0 0 
136 64200   
152 45 48787  
285 49 36  
470  52 69 
590 0 0 0 
613  0  
644 0 0  
672  15  
688 0 0 0 
707 0 0 0 
750 14 2959 0 
755 0 0  
847  79043 3120 
918 0 0 0 
935 0 32 0 
1010 50 23 0 
1014  0  
1039 65 63  
1054 0 0 0 
1057 0 0  
1084 201 125  
1095 74020 194  
1218 6104 0 0 
1256  5255 0 
2021 0 0 0 
2056 45 0 0 
2058 31  64909 
2225 15 12 4 
2388 373 0 0 
2410 323 486 0 
2418 45 9 0 
2433 0 0 0 
2441 336 0 5 
112 
 
2461 10 0 0 
2495 11 0 0 
2496 0 295 0 
2498 0 0  
2500 0 28 0 
2509 34 0 0 
2538 6094   
2539 27116 156 26433 
2556 12 24  
2568 34700 0 0 
2575 42200   
2594 17050 0 0 
2595 42  0 
2612 0 62500 0 
2614 31 483  
2630  0 0 
2645 14047 10 0 
2652 29500 12 0 
2653 2515 80 27 
2654 20855 0 0 
2655 76 0 0 
2659 46 11 12 
2661 1587 4962 0 
2663 95033 0 0 
2664 30841 19175 0 
2665 14603 0 0 
2668 138058 9080  
2670 10393 7622 0 
2671 336 158 0 
2672 106773 57000 57000 
2673 54970 40  
2676 15753 0 0 
2678 12352 2300 0 
2682 10463 0 0 
2684 5960 1595 0 
2688 21075 78 0 
2690 106379 27  
2691 71674 10  
2692 170597 55  
2693 353449 0 0 
2695 123992 19  
2697 552767 20 14 
2699 19 0  
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2702 476 117 358 
2705 6850 0 0 
2706 13991 46  
2709 11100 1425 0 
2710 2200 0 0 
2715 2200 0 0 
2749 9200 6903 4513 
2751 13 0 0 
2752 46809 5 0 
2753 22568 9 0 
2760 36709 17 0 
2762 171573 8 0 
2764 93472 0 0 
2765 1695 0  
2771 103746 15 0 
2773 1005 0  
2774 546469 20  
2775 100 0 0 
2776 22008   
2778 70018 4 0 
2779 34409   
2780 214546 0 0 
2781 143600 0 20 
2782 38917  0 
2783 1009 8 1 
2784 95170 10 1951 
2785 10004 4 20 
2787  34 12 
2788 238 28 5 
2790 12770 15 0 
2791 6044 0 3 
2793 97789 0  
2794 90422 33  
2795 32797 0  
2796 33162 0  
2797 77838 0  
2798 6787 0  
2799 140091 0  
2801 3677 0  
2802 37823 0 0 
2805 1092 49219 0 
2807 4525   
2808 61464 30  
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2809 243159 152 37 
2812 69186   
2815 24398 87  
2819 512100   
2825 9876 25  
2826 141671 13 7 
2827 18761 11 0 
2829 323055 12  
2837 11718 1495 0 
2844 44500 170  
2846 18400 15900  
2847 4290 0 0 
2848 215000 0  
2856 22486 0  
2859  18090 0 
2860  83593 13 
2861  12856 0 
2862  165261 6 
2863  89232 28 
2865  37 0 
2887  277002 0 
2892  7578 18 
2903  47040 0 
2924 193 218 3 
2925  75641 9 
2926  538 0 
2928 3500 1686 3 
2929  350 0 
2930  22426 0 
2936 307643 28 8 
2939  9219 17 
2940 6874 261  
2943  276200 20 
2945 1610 828 0 
2946 72751 82  
2947 53824 0 0 
2948 42775 0  
2952  3340 0 
2953  7686 0 
2956  23050  
2958  31  
2960  836 0 
2961  7050  
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2962 5450 1037 0 
2964  6700  
2965  837419 24 
2966  8598 0 
2967 51200 46754 0 
2976 16192 11  
2977 32840 16  
3260  8506 13 
3364  69174  
3466  3050 9 
3468  47530 8 
3513 244618 28 0 
3514 32906 20  
3515 12876 0 0 
3549 64046 0  
3648  8926 12 
3649  205672  
3650  28859  
3651 14533   
3675  169140 0 
3677  1080 0 
3678  37416  
3679  6250 0 
3680  49190 0 
3681  70280 0 
3682  10459  
3683  60 0 
3684  24428 0 
3685  260487  
3686  8671  
3687 336723 20 0 
3688 784548 122134 696 
3689 5872 20 0 
3690 30191 20 0 
3691 379613 680 0 
3692  27789  
3744 90878 56  
3769 5712 0  
3778 124388 34  
3847 795 0  
3848  367331 12 
3869 51236 0  
3876 14551 19  
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3877  45730  
3879 57745 14  
3880  9262  
3881  14925  
3882  15298  
3883  26014  
3884 4305 0  
3885 67735 0  
3910  54975 15 
3924  45481 13 
3963  1060327 419 
3964 5840 4590 0 
3965  0 0 
4008  19  
4023  1759 25 
4050  0  
4075  307  
4118  19  
4147  2200 5 
4247  34400 84 
4249  193000  
4251 20500 23444 0 
4252  0 109 
4255  37254 0 
4256  45048 0 
4257  12449  
4258  0  
4277  0  
4291  9028  
4292  2500047  
4293  43816  
4294  799  
4295  799056  
4297 44799 0  
4300  22890 0 
4301  6708  
4309 74132 0  
4322 48605 0  
4329  19  
4330  0  
4331  0  
4332  0  
4333  37045  
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4334  2188  
4335  25826 40 
4336  16206 239 
4337  3163 0 
4338  881894 94 
4348  6233  
4349  38171 0 
4350  500066 0 
4351  737538  
4352  900376 400 
4353  576  
4354  83236  
4355  29161 29 
Average 57252 68231 1602 
Std Dev 113849 210728 7267 
    
T TEST 2015-2016 0,595138798   
T TEST 2016-2017 0,000421452   
 
A1.2 CD4 
 Average CD4 value  
Patient ID 2015 2016 2017 
106 1097 924 1238 
107 477 500 465 
136 36     
152 316 246 220 
285 940 792 810 
470 727 704 891 
590 587 495 637 
613 1427 1408   
644 333 270 273 
672   435   
688 742 829 748 
707 687 656 903 
750 826 812 678 
755 1621 1809 1863 
847   123 157 
918 371 483 409 
935 645 774 859 
1010 425 499 478 
1014 444 507 417 
1039 1057 1116 1108 
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1054 453 531 578 
1057 506 579   
1084 375 457 355 
1095 541 744   
1218 425 666 650 
1256   849 1264 
1788   100   
2021 856 719 872 
2056 309 369 465 
2058 295   65 
2225 217 202 290 
2388 517 509 598 
2410 815 734 816 
2418 447 588 707 
2433 805 945 1156 
2441 495 625 676 
2461 679 671 783 
2495 256 461 557 
2496 477 683 745 
2498 141 202 308 
2500 353 324 372 
2509 753 808 964 
2538 527     
2539 408 646 269 
2556 605 727 681 
2568 467 600 530 
2575 150 185   
2594 630 708 913 
2595 832 896 869 
2612 511 491 598 
2614 542 628 535 
2630 720 724 863 
2645 840 916 777 
2652 725 641 634 
2653 125 422 573 
2654 819 1219 1020 
2655 106 197 168 
2659 283 318 365 
2661 612 567 716 
2663 358 619 434 
2664 596 696 772 
2665 588 975 999 
2668 239 709   
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2670 479 742 867 
2671 795 789 821 
2672 442 600 748 
2673 438 785 867 
2676 421 578 676 
2678 730 902 1274 
2682 514 722 573 
2684 453 505 736 
2688 494 703 836 
2690 183 318   
2691 924 1282   
2692 73 154   
2693 412 579 530 
2695 420 438   
2697 187 456 498 
2699 624 1531   
2702 271 352 405 
2705   318   
2706 927 1002   
2709 717 686 944 
2710 507 659 716 
2715 372 587 579 
2749 733 542 474 
2751 599 640 618 
2752 326 518 526 
2753 604 748 841 
2760 266 506 476 
2762 217 441 526 
2764 177 370 385 
2765 916 811   
2771 39 101 202 
2773 444 501   
2774 573 797   
2775 281 313 420 
2776 674     
2778 818 824 922 
2779 557 953 895 
2780 111 264 354 
2781 121 500 310 
2782 472 519 549 
2783   1153 1124 
2784 152 192 170 
2785 598 835 952 
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2787   556 602 
2788   230 212 
2790 167 289 348 
2791 248 433 385 
2793 101 121   
2794 273 687   
2795 216 397   
2796 568 514   
2797 299 364   
2798 714 816   
2799 386 528   
2801 395 343   
2802 987 1147 1370 
2805 867 869 1164 
2807 591     
2808 688 1131 1212 
2809 88 275 392 
2812 89     
2815 362 942 805 
2819 261     
2825 391 710   
2826 214 355 366 
2827 304 421 427 
2829 102 122   
2837 438 529 548 
2844 600 603   
2846 485 508   
2847 420 712 606 
2848 122 324 456 
2856 835 818   
2859   211 403 
2860   47 207 
2861   431 495 
2862   767 902 
2863   250 273 
2865   413 450 
2887   698 864 
2892   79 136 
2903   971 1481 
2924 1093 841 981 
2925   184 477 
2926   700 448 
2928 758 678 813 
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2929   795 745 
2930   440 577 
2936 80 231 216 
2939   285 461 
2940 361 362   
2943   600 954 
2945 447 457 562 
2946 114 266 326 
2947 131 278 356 
2948 96 168   
2952   814 940 
2953   372 385 
2956   139 337 
2958   584   
2960   267 370 
2961   321   
2962 368 585 617 
2964   579 652 
2965   7 39 
2966   449 558 
2967 561 444 651 
2976 205 363   
2977 809 888   
3260   724 614 
3364   41   
3466   103 159 
3468   553 896 
3513 0 100   
3514 280 690   
3515 300     
3549 474 448   
3648   688 772 
3649   282   
3650   593   
3651 400     
3675   142 278 
3677   259 369 
3678   491 708 
3679   533 584 
3680   1313 1329 
3681   1076 1352 
3682   132 215 
3683   273 428 
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3684   207 327 
3685   135   
3686   490   
3687 550 940   
3688 0 110   
3689 130 230   
3690 340 350   
3691 330 720   
3744 159 230   
3769 48 108   
3778 107 361   
3847 483 946   
3848   68 198 
3869 681 996   
3876 499 644   
3877   234   
3879 207 246   
3880   730   
3882   641   
3883   475   
3884 667 487   
3885 12 3   
3910   484 1160 
3924   168 473 
3963   165 131 
3964 531 493 561 
3965   802 1000 
4008   263   
4023   495 531 
4050   605   
4075   374   
4118   553   
4147   467 732 
4247   498   
4249   2   
4251 918 791 1192 
4252   248 380 
4255   478 823 
4256   425 734 
4257   303 432 
4258   932 955 
4277   321   
4291   864   
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4292   939   
4293   37   
4294   569   
4295   48   
4297 383 549   
4300   655 255 
4301   732   
4309 565 625   
4322 902 937   
4329   1494   
4330   1203   
4331   1412   
4332   1449   
4333   164   
4334   755   
4335   730 730 
4336   450   
4337   780   
4338   80   
4348   355   
4349   510   
4350   35   
4351   130   
4352   50   
4353   370   
4354   220   
4355   70   
Average 489 548 637 
Std Dev 282 318 317 
    
T TEST 2015-2016 0,014904603   
T TEST 2016-2017 0,005814978 p<0,01  
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A2 Therapy adherence 
Patient ID 2015 2016 2017 
14544   0,2 0,5 
14647   0,3   
15176     1,0 
15393   1,0   
15404   0,4 0,5 
15574   0,2   
15581   0,2   
16239   0,3   
16281   0,7 0,5 
16447   0,2 1 
51867   0,1   
53070   0,6 0,5 
53225   0,7   
55708   0,2   
55977   0,4 1 
56812   1,0 1,0 
59127   0,2 0,5 
59178   0,7 0,3 
60853   1 1 
61947   1,0 0,8 
62972   0,7 1 
65757     0,3 
67587     1,0 
70896 0,7     
71311     0,5 
71734   0,4   
72547     0,3 
72730 1 1,0 1,0 
73434 0,5 0,4 1,0 
73648     1,0 
74753     0,3 
75461   0,2 0,5 
75798     0,5 
76121   0,7 1 
77198   1 1 
79503   0,2   
80264     0,8 
81129   0,8 1,0 
83563   0,2 0,3 
83790   0,7 0,5 
84443   0,7 1 
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86640   0,8 0,8 
87731   0,1   
87985   0,3 1 
89520 1 1 1,0 
89656     0,5 
89885 1 0,9 1 
90260 0,7 1 1,0 
90396 1,0 1,0 1,0 
90853   0,9 1 
91329 0,9 1,0 1,0 
91383 0,9 1,0 1,0 
91606   0,7 1,0 
91993 0,7 1,0 1,0 
92075 0,7 1 1,0 
92232 0,6 1,0 1 
92573 0,6 0,9 0,8 
93672 0,7 1 0,5 
93699 0,2 1,0 0,8 
93806 0,5 1,0 1,0 
93849 0,3     
94220   1 1,0 
94309 0,1     
94414 0,6 1 1,0 
94610   0,9 1 
94793 0,5 0,9 1,0 
95313 0,5 0,9 1,0 
95395 0,2 1 1,0 
95560 0,3 1,0 1 
95574 0,3 1,0 1 
95585   0,7 1,0 
95683   0,5   
96619   0,1   
96817 0,2 1,0 1,0 
97033 0,2 1,0 1,0 
97166 0,2 1,0 0,8 
98029   0,7 0,5 
98164   1 0,8 
98183   0,1   
98192   0,6 1,0 
98246   0,5   
98487   1,0 1,0 
98580   1 1,0 
98889   0,5 1 
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99115   1,0 1,0 
99518   1 1 
99657   0,8 1 
100235   0,8 0,5 
100589   0,8 1 
100783   0,1   
100957   0,8 1,0 
101327   0,7 1,0 
101357   0,8 1,0 
101395   0,2   
101417   0,8   
101419   0,2 1,0 
101494   0,4 0,3 
101744   0,8 1 
101963   0,7 1,0 
102030   0,2   
102122     1 
102211   0,7 1 
102250   0,2   
102389   0,6 1 
102640   0,7 1,0 
103049   0,7 0,3 
103111   0,1   
103145   0,5 1,0 
103289   0,7 0,5 
103320   0,6 1 
103492   0,6 1,0 
103529   0,7 1,0 
103828   0,6 0,5 
104107   0,5 1,0 
104189   0,5 1,0 
104269 0,4 0,9 1 
104359   0,3 1 
104427   0,4 0,8 
104584   0,4 1,0 
104641   0,1   
104665   0,3 1 
104729   0,5 0,8 
104816   0,2 1 
105009   0,3 1 
105089   0,4 0,8 
105171   0,2 0,5 
105256   0,3 1,0 
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105311   0,1   
105862   0,4 1,0 
106041   0,2 1,0 
106201   0,1   
106461   0,2 0,3 
106529   0,1   
106701     1 
107163   0,2 1,0 
107193   0,1   
107529     1 
108409     0,3 
108433     0,3 
108444     1 
109049     1 
109364     0,8 
110123     0,5 
110173     0,5 
110508     0,3 
110577     0,3 
2995     0,3 
3727     0,3 
Average 0,5 0,6 0,7 
Std Dev 0,3 0,3 0,3 
    
T TEST 2015-2016 0,342590479   
T TEST 2016-2017 1,72004E-05   
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A3 HAART prescription appropriateness 
Patient ID Prescription date Active drugs Score Price 
2851 01/01/2015 TDF/FTC+RAL 0,69 960,39 
2980 01/01/2015 MVC 0,033 903,16 
2978 01/01/2015 3TC+MVC 0,027 964,21 
2989 01/01/2015 r+MVC+DRV 0,001 1250,94 
2979 01/01/2015 DRV+r+MVC 0,001 1250,94 
2986 01/01/2015 MVC+ABC/3TC 0,001 1301,35 
2984 01/01/2015 3TC+r+MVC+DRV 0,001 1311,99 
2991 01/01/2015 MVC+TDF+FTC+EVG+COBI 0,001 1341,62 
2990 01/01/2015 TDF/FTC+MVC 0,001 1342,02 
2981 01/01/2015 RAL+MVC 0,001 1424,69 
2987 01/01/2015 3TC+MVC+DTG 0,001 1510,01 
2985 01/01/2015 r+MVC+DRV+TDF 0,001 1527,92 
2982 01/01/2015 MVC+RPV+DTG 0,001 1679,72 
2988 01/01/2015 RAL+DRV+r+MVC 0,001 1772,47 
2983 01/01/2015 MVC+DTG+ATV 0,001 1781,93 
2822 02/01/2015 TDF/FTC+RAL 0,69 960,39 
2388 09/01/2015 TDF+FTC+RPV 1 669,22 
2441 13/01/2015 TDF/FTC+DRV+r 0,88 786,64 
2418 20/01/2015 DTG+ABC/3TC 0,71 943,99 
2805 21/01/2015 DRV+RAL+RTV 0,106 894,28 
2490 26/01/2015 TDF+FTC+RPV 1 669,22 
1310 27/01/2015 DTG+ABC/3TC 0,71 943,99 
1419 03/02/2015 TDF+FTC+RPV 1 669,22 
2969 03/02/2015 RAL+DRV+r+ABC/3TC 0,001 1267,5 
2793 03/02/2015 DRV+RAL+ABC/3TC 0,001 1267,5 
2654 10/02/2015 TDF+FTC+RPV 1 669,22 
2676 20/02/2015 TDF+FTC+RPV 1 669,22 
2808 20/02/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2975 23/02/2015 RAL+MVC+ABC/3TC 0,001 1822,88 
2794 26/02/2015 3TC+DRV+r+RAL 0,033 930,36 
2795 27/02/2015 DTG+ABC/3TC 0,71 943,99 
2645 12/03/2015 TDF+FTC+RPV 1 669,22 
2784 19/03/2015 TDF/FTC+DRV+r 0,88 786,64 
2655 19/03/2015 TDF/FTC+RTV+ATV 0,122 796,8 
107 20/03/2015 TDF+FTC+RPV 1 669,22 
2947 24/03/2015 TDF/FTC+RTV+ATV 0,122 796,8 
2946 24/03/2015 DRV+RTV+DTG+ETR 0,001 1314,55 
2691 30/03/2015 TDF+FTC+EVG+COBI 0,41 904,56 
4297 02/04/2015 TDF/FTC/EVG/COBI 0,75 904,56 
2692 08/04/2015 TDF/FTC+r+DRV 0,88 786,64 
2791 10/04/2015 TDF/FTC+DTG 0,6 1038,86 
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2693 13/04/2015 TDF/FTC+DTG 0,6 1038,86 
2767 14/04/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2690 16/04/2015 TDF/FTC+RTV+ATV 0,122 796,8 
1218 21/04/2015 TDF+FTC+RPV 1 669,22 
2663 22/04/2015 DTG+ABC/3TC 0,71 943,99 
2976 27/04/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2755 27/04/2015 TDF/FTC+RAL 0,69 960,39 
2665 04/05/2015 TDF+FTC+RPV 1 669,22 
2770 04/05/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2766 04/05/2015 TDF/FTC+DTG 0,6 1038,86 
2779 05/05/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2695 11/05/2015 TDF/FTC+r+DRV 0,88 786,64 
2697 13/05/2015 TDF/FTC+DTG 0,6 1038,86 
2764 18/05/2015 TDF/FTC+DRV+r 0,88 786,64 
2790 22/05/2015 TDF/FTC+r+DRV 0,88 786,64 
2797 27/05/2015 TDF/FTC+DTG 0,6 1038,86 
2056 29/05/2015 TDF+FTC+RPV 1 669,22 
2796 29/05/2015 TDF/FTC+DTG 0,6 1038,86 
2949 18/06/2015 RAL+r+fAPV 0,033 837,82 
2699 22/06/2015 DTG+ABC/3TC 0,71 943,99 
2705 28/06/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2706 29/06/2015 TDF+FTC+EVG+COBI 0,41 904,56 
3847 29/06/2015 DTG+ABC/3TC 0,71 943,99 
2776 01/07/2015 TDF+FTC+RPV 1 669,22 
2780 01/07/2015 TDF/FTC+DTG 0,6 1038,86 
2948 02/07/2015 TDF/FTC+RAL 0,69 960,39 
2785 07/07/2015 TDF/FTC+DTG 0,6 1038,86 
2829 09/07/2015 TDF/FTC+RAL 0,69 960,39 
183 10/07/2015 TDF+FTC+RPV 1 669,22 
2771 15/07/2015 TDF/FTC+DTG 0,6 1038,86 
2640 17/07/2015 TDF+FTC+RPV 1 669,22 
2689 20/07/2015 TDF+FTC+RPV 1 669,22 
2812 24/07/2015 DTG+ABC/3TC 0,71 943,99 
2826 27/07/2015 TDF/FTC+DTG 0,6 1038,86 
2710 28/07/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2650 29/07/2015 ABC+3TC+RAL 0,425 807,16 
4309 03/08/2015 TDF+FTC+RPV 1 669,22 
2798 03/08/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2807 04/08/2015 TDF+FTC+RPV 1 669,22 
3885 05/08/2015 TDF/FTC+r+DRV 0,88 786,64 
3688 05/08/2015 TDF/FTC+r+DRV 0,88 786,64 
2815 06/08/2015 TDF+FTC+RPV 1 669,22 
2781 10/08/2015 TDF/FTC+DRV+RTV 0,119 811,61 
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3549 11/08/2015 TDF+FTC+RPV 1 669,22 
2664 12/08/2015 TDF+FTC+RPV 1 669,22 
3687 14/08/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2752 18/08/2015 TDF/FTC+DTG 0,6 1038,86 
2963 25/08/2015 TDF/FTC+r+DRV 0,88 786,64 
3690 26/08/2015 TDF+FTC+RPV 1 669,22 
2782 31/08/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2715 01/09/2015 DTG+ABC/3TC 0,71 943,99 
2760 01/09/2015 TDF/FTC+DTG 0,6 1038,86 
3689 04/09/2015 TDF+FTC+EVG+COBI 0,41 904,56 
3513 09/09/2015 TDF/FTC+r+DRV 0,88 786,64 
2708 11/09/2015 TDF/FTC+DTG 0,6 1038,86 
3515 15/09/2015 TDF+FTC+RPV 1 669,22 
3769 15/09/2015 DTG+ABC/3TC 0,71 943,99 
2765 21/09/2015 DTG+ABC/3TC 0,71 943,99 
2799 22/09/2015 DTG+ABC/3TC 0,71 943,99 
2768 22/09/2015 TDF/FTC+RAL 0,69 960,39 
2809 22/09/2015 TDF/FTC+DTG 0,6 1038,86 
2773 23/09/2015 DTG+ABC/3TC 0,71 943,99 
2774 29/09/2015 TDF/FTC+DTG 0,6 1038,86 
2682 01/10/2015 TDF+FTC+RPV 1 669,22 
2673 01/10/2015 TDF+FTC+EVG+COBI 0,41 904,56 
3879 07/10/2015 TDF/FTC+DTG 0,6 1038,86 
3691 08/10/2015 TDF/FTC+r+DRV 0,88 786,64 
2668 08/10/2015 TDF/FTC+DRV+RAL+RTV 0,001 1308,17 
2778 09/10/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2801 15/10/2015 TDF+FTC+RPV 1 669,22 
3744 28/10/2015 TDF/FTC+r+DRV 0,88 786,64 
2678 29/10/2015 TDF+FTC+RPV 1 669,22 
3846 29/10/2015 TDF/FTC+RPV 1 669,62 
2827 30/10/2015 TDF+FTC+RPV 1 669,22 
2802 09/11/2015 TDF+FTC+RPV 1 669,22 
2783 11/11/2015 TDF+FTC+RPV 1 669,22 
2847 12/11/2015 TDF+FTC+RPV 1 669,22 
3514 12/11/2015 DTG+ABC/3TC 0,71 943,99 
2856 18/11/2015 TDF+FTC+RPV 1 669,22 
3876 23/11/2015 TDF+FTC+RPV 1 669,22 
2788 23/11/2015 TDF/FTC+RAL 0,69 960,39 
4322 24/11/2015 TDF/FTC/RPV 1 650,86 
4322 24/11/2015 TDF+FTC+RPV 1 669,22 
2672 24/11/2015 TDF+FTC+EVG+COBI 0,41 904,56 
2789 24/11/2015 DRV+r+ABC/3TC 0,874 745,97 
2848 26/11/2015 RTV+DRV+ABC/3TC 0,125 770,94 
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2819 26/11/2015 TDF+FTC+EVG+COBI 0,41 904,56 
3778 30/11/2015 TDF/FTC+r+DRV 0,88 786,64 
2950 11/12/2015 r+ABC/3TC+ATV 0,94 731,16 
2852 22/12/2015 r+DTG+DRV 0,033 893,58 
2787 29/12/2015 TDF/FTC+DTG 0,6 1038,86 
2940 11/01/2016 TDF/FTC/RPV 1 650,86 
2844 12/01/2016 TDF/FTC/RPV 1 650,86 
2684 18/01/2016 TDF/FTC/RPV 1 650,86 
2977 26/01/2016 TDF/FTC/EVG/COBI 0,75 904,56 
2837 28/01/2016 TDF/FTC/EVG/COBI 0,75 904,56 
2956 28/01/2016 TDF/FTC/EVG/COBI 0,75 904,56 
2945 09/02/2016 TDF/FTC/RPV 1 650,86 
2962 15/02/2016 ABC/3TC+DRV+r 0,372 745,97 
2958 18/02/2016 TDF/FTC/EVG/COBI 0,75 904,56 
2863 25/02/2016 TDF/FTC+DTG 0,6 1038,86 
2952 02/03/2016 ABC/3TC+DRV+r 0,372 745,97 
2887 03/03/2016 TDF/FTC+DTG 0,6 1038,86 
3685 05/03/2016 TDF/FTC/EVG/COBI 0,75 904,56 
3877 09/03/2016 TDF/FTC+DRV+r 0,44 786,64 
2749 11/03/2016 TDF/FTC/RPV 1 650,86 
2862 11/03/2016 TDF/FTC+EFV 0,4 653,49 
2709 15/03/2016 TDF/FTC/RPV 1 650,86 
2865 17/03/2016 TDF/FTC/EVG/COBI 0,75 904,56 
2964 22/03/2016 TDF/FTC/EVG/COBI 0,75 904,56 
3880 30/03/2016 TDF/FTC+DTG 0,6 1038,86 
2670 04/04/2016 TDF/FTC/RPV 1 650,86 
2953 11/04/2016 TDF/FTC/EVG/COBI 0,75 904,56 
4337 12/04/2016 TDF/FTC/RPV 1 650,86 
2892 14/04/2016 3TC+TDF+RAL 0,28 860,55 
2702 15/04/2016 TDF/FTC/RPV 1 650,86 
106 18/04/2016 TDF/FTC/RPV 1 650,86 
2960 19/04/2016 TDF/FTC/RPV 1 650,86 
3686 19/04/2016 ABC/3TC/DTG 0,65 998,19 
2961 20/04/2016 TDF/FTC/EVG/COBI 0,75 904,56 
4338 21/04/2016 DRV+r+RAL 0,316 869,31 
4334 26/04/2016 TDF/FTC/RPV 1 650,86 
2943 26/04/2016 TDF/FTC/EVG/COBI 0,75 904,56 
3965 12/05/2016 TDF/FTC/EFV 0,4 653,32 
4294 17/05/2016 TDF/FTC/RPV 1 650,86 
3649 19/05/2016 ABC/3TC+DTG 0,65 998,19 
2661 24/05/2016 ABC/3TC/DTG 0,65 998,19 
3964 24/05/2016 TDF/FTC+DTG 0,6 1038,86 
2926 01/06/2016 TDF/FTC/RPV 1 650,86 
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2967 01/06/2016 TDF/FTC/RPV 1 650,86 
2930 13/06/2016 TDF/FTC/RPV 1 650,86 
2929 13/06/2016 TDF/FTC/EVG/COBI 0,75 904,56 
3675 16/06/2016 TDF/FTC/EVG/COBI 0,75 904,56 
2928 21/06/2016 TDF/FTC/RPV 1 650,86 
3650 28/06/2016 TDF/FTC/RPV 1 650,86 
4291 29/06/2016 TDF/FTC/RPV 1 650,86 
2671 01/07/2016 TDF/FTC/RPV 1 650,86 
4252 01/07/2016 TDF/FTC/EFV 0,4 653,32 
2410 14/07/2016 TDF/FTC/RPV 1 650,86 
3882 18/07/2016 TDF/FTC/RPV 1 650,86 
3679 18/07/2016 TDF/FTC/EVG/COBI 0,75 904,56 
4301 19/07/2016 ABC/3TC+DTG 0,65 998,19 
4354 19/07/2016 TDF/FTC+DRV+r 0,44 786,64 
3677 22/07/2016 TDF/FTC+RAL 0,69 960,39 
4257 28/07/2016 TDF/FTC+DRV/COBI 0,44 786,64 
3883 01/08/2016 TDF/FTC/RPV 1 650,86 
3466 03/08/2016 TDF/FTC+DTG 0,6 1038,86 
3681 05/08/2016 TDF/FTC/RPV 1 650,86 
3468 05/08/2016 DRV/COBI+DTG 0,028 947,78 
3881 09/08/2016 TDF/FTC/RPV 1 650,86 
3678 11/08/2016 TDF/FTC/EVG/COBI 0,75 904,56 
3682 12/08/2016 TDF/FTC/EVG/COBI 0,75 904,56 
3364 14/08/2016 TDF/FTC+DTG 0,6 1038,86 
3683 01/09/2016 TDF/FTC+DTG 0,6 1038,86 
4258 07/09/2016 TDF/FTC/RPV 1 650,86 
4293 13/09/2016 TDF/FTC+r+DRV 0,44 786,64 
1256 14/09/2016 TDF/FTC/RPV 1 650,86 
3648 16/09/2016 TDF/FTC/EVG/COBI 0,75 904,56 
4256 20/09/2016 TDF/FTC+DTG 0,6 1038,86 
4251 27/09/2016 TDF/FTC/RPV 1 650,86 
3684 28/09/2016 TDF/FTC/RPV 1 650,86 
4249 28/09/2016 TDF/FTC/EVG/COBI 0,75 904,56 
4353 29/09/2016 TDF/FTC/RPV 1 650,86 
4300 08/10/2016 DRV/COBI+DTG 0,028 947,78 
4293 10/10/2016 TDF/FTC+r+DRV 0,44 786,64 
4349 12/10/2016 TDF/FTC/EVG/COBI 0,75 904,56 
4147 13/10/2016 TDF/FTC+DTG 0,6 1038,86 
4336 17/10/2016 TDF/FTC/RPV 1 650,86 
3848 20/10/2016 TDF/FTC+DTG 0,6 1038,86 
4255 21/10/2016 TDF/FTC/EVG/COBI 0,75 904,56 
3680 21/10/2016 ABC/3TC/DTG 0,65 998,19 
4350 25/10/2016 TDF/FTC+DTG 0,6 1038,86 
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3910 28/10/2016 TDF/FTC/EVG/COBI 0,75 904,56 
3924 08/11/2016 TDF/FTC/EVG/COBI 0,75 904,56 
4351 14/11/2016 TDF/FTC/EVG/COBI 0,75 904,56 
4355 28/11/2016 ABC/3TC/DTG 0,65 998,19 
4247 30/11/2016 TDF/FTC/RPV 1 650,86 
4023 14/12/2016 TDF/FTC/RPV 1 650,86 
4295 19/12/2016 TDF/FTC+DRV+r 0,44 786,64 
4335 22/12/2016 ABC/3TC/DTG 0,65 998,19 
4352 13/01/2017 TDF/FTC/EVG/COBI 0,75 904,56     
 
  
Average score 2015: 0,60    
Average score 2016: 0,75    
Student’s T test 0,0001674  
     
  Average price 2015: 919,60  
  Average price 2016: 816,18  
  Student’s T test 0,0001441  
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Appendix B: SOAP 
messages 
B1 KM1 Naive NRTI 
B1.1 Request 
<s:Envelope xmlns:s="http://schemas.xmlsoap.org/soap/envelope/"> 
  <s:Header> 
    <To s:mustUnderstand="1" 
xmlns="http://schemas.microsoft.com/ws/2005/05/addressing/none">http://localhost:27956/SimpleEvaluation.sv
c</To> 
    <Action s:mustUnderstand="1" 
xmlns="http://schemas.microsoft.com/ws/2005/05/addressing/none">http://www.omg.org/spec/CDSS/201012/ds
sWsdl/ISimpleEvaluation/Evaluate</Action> 
  </s:Header> 
  <s:Body xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xmlns:xsd="http://www.w3.org/2001/XMLSchema"> 
    <evaluate xmlns="http://www.omg.org/spec/CDSS/201012/dss"> 
      <interactionId scopingEntityId="it.hsanmartino.cds" interactionId="979aa143ff8a4cb294b56afb988f2d32" 
submissionTime="2017-04-07T10:05:18.4763818Z" xmlns=""></interactionId> 
      <evaluationRequest clientLanguage="it-IT" clientTimeZoneOffset="+01:00" xmlns=""> 
        <kmEvaluationRequest> 
          <kmId scopingEntityId="it.medinfo.km" businessId="NAIVESceltaNRTI" version="1.0"></kmId> 
        </kmEvaluationRequest> 
        <dataRequirementItemData> 
          <driId itemId="RequiredDataId"></driId> 
          <data> 
            <informationModelSSId scopingEntityId="org.hl7.cds" businessId="cdsinput:r2:CDSInput" 
version="2.0"></informationModelSSId> 
            <base64EncodedPayload> 
              <patient xmlns="urn:hl7-org:vmr:r2"> 
                <id root="2.16.840.1.113883.2.9.3.17.3.2.1.4" extension="00901115"></id> 
                <gender code="M" codeSystem="2.16.840.1.113883.5.1" 
codeSystemName="AdministrativeGender"></gender> 
                <birthTime value="19610711"></birthTime> 
                <age value="56" unit="years"></age> 
                <clinicalStatement xsi:type="ObservationResult"> 
                  <id root="00901115.201704070000.50956-2"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <observationFocus code="50956-2" codeSystem="2.16.840.1.113883.6.1" 
codeSystemName="LOINC"></observationFocus> 
                  <observationValue> 
                    <value xsi:type="q1:PQ" value="1" unit="" xmlns:q1="urn:hl7-org:cdsdt:r2"></value> 
                  </observationValue> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="DeniedProblem"> 
                  <id root="00901115.201704070000.4292"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <conditionCode code="4292" codeSystem="2.16.840.1.113883.6.103" codeSystemName="ICD-9-
CM"></conditionCode> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="Problem"> 
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                  <id root="00901115.201704070000.7330"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <conditionCode code="7330" codeSystem="2.16.840.1.113883.6.103" codeSystemName="ICD-9-
CM"></conditionCode> 
                  <conditionEffectiveTime lowClosed="true"> 
                    <low value="20120207" xmlns="urn:hl7-org:cdsdt:r2"></low> 
                  </conditionEffectiveTime> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="DeniedProblem"> 
                  <id root="00901115.201704070000.0703"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <conditionCode code="0703" codeSystem="2.16.840.1.113883.6.103" codeSystemName="ICD-9-
CM"></conditionCode> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="ObservationResult"> 
                  <id root="00901115.201704070000.20447-9"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <observationFocus code="20447-9" codeSystem="2.16.840.1.113883.6.1" 
codeSystemName="LOINC"></observationFocus> 
                  <observationValue> 
                    <value xsi:type="q2:PQ" value="33" unit="Copie/ml" xmlns:q2="urn:hl7-org:cdsdt:r2"></value> 
                  </observationValue> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="ObservationResult"> 
                  <id root="00901115.201704070000.30525-0"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <observationFocus code="30525-0" codeSystem="2.16.840.1.113883.6.1" 
codeSystemName="LOINC"></observationFocus> 
                  <observationValue> 
                    <value xsi:type="q3:PQ" value="56" unit="Years" xmlns:q3="urn:hl7-org:cdsdt:r2"></value> 
                  </observationValue> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="DeniedProblem"> 
                  <id root="00901115.201704070000.011"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <conditionCode code="011" codeSystem="2.16.840.1.113883.6.103" codeSystemName="ICD-9-
CM"></conditionCode> 
                </clinicalStatement> 
              </patient> 
            </base64EncodedPayload> 
          </data> 
        </dataRequirementItemData> 
      </evaluationRequest> 
    </evaluate> 
  </s:Body> 
</s:Envelope> 
B1.2 Response 
<s:Envelope xmlns:s="http://schemas.xmlsoap.org/soap/envelope/"> 
  <s:Header> 
    <Action s:mustUnderstand="1" 
xmlns="http://schemas.microsoft.com/ws/2005/05/addressing/none">http://www.omg.org/spec/CDSS/201012/ds
sWsdl/ISimpleEvaluation/EvaluateResponse</Action> 
  </s:Header> 
  <s:Body xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xmlns:xsd="http://www.w3.org/2001/XMLSchema"> 
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    <evaluateResponse xmlns="http://www.omg.org/spec/CDSS/201012/dss"> 
      <evaluationResponse xmlns=""> 
        <finalKMEvaluationResponse> 
          <kmId scopingEntityId="it.medinfo.km" businessId="NAIVESceltaNRTI" version="1.0"></kmId> 
          <kmEvaluationResultData> 
            <evaluationResultId itemId="76bb25b9-476b-47a0-9b54-2e9148e5e38b"></evaluationResultId> 
            <data> 
              <informationModelSSId scopingEntityId="org.hl7.cds" businessId="cdsoutput:r2:CDSOutputAsVMR" 
version="2.0"></informationModelSSId> 
              <base64EncodedPayload> 
                <templateId root="2.16.840.1.113883.3.1829.11.1.3.5" identifierName="CDSOutputAsVMR" 
xmlns="urn:hl7-org:vmr:r2"></templateId> 
                <patient xmlns="urn:hl7-org:vmr:r2"> 
                  <id root="2.16.840.1.113883.2.9.3.17.3.2.1.4" extension="00901115"></id> 
                  <gender code="M" codeSystem="2.16.840.1.113883.5.1" 
codeSystemName="AdministrativeGender"></gender> 
                  <birthTime value="19610711"></birthTime> 
                  <age value="56" unit="years"></age> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AF07J05AF09"></id> 
                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
                      <name value="Recommended"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q1="urn:hl7-org:cdsdt:r2" xsi:type="q1:INT" value="2"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <relatedEntity> 
                        <entity xsi:type="AdministrableSubstance"> 
                          <substanceCode code="J05AF09" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                        </entity> 
                      </relatedEntity> 
                      <substanceCode code="J05AF07" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                    </substance> 
                  </clinicalStatement> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AF06J05AF05"></id> 
                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
                      <name value="Acceptable alternative"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q2="urn:hl7-org:cdsdt:r2" xsi:type="q2:INT" value="1"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <relatedEntity> 
                        <entity xsi:type="AdministrableSubstance"> 
                          <substanceCode code="J05AF05" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                        </entity> 
                      </relatedEntity> 
                      <substanceCode code="J05AF06" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
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                    </substance> 
                  </clinicalStatement> 
                </patient> 
              </base64EncodedPayload> 
            </data> 
          </kmEvaluationResultData> 
        </finalKMEvaluationResponse> 
      </evaluationResponse> 
    </evaluateResponse> 
  </s:Body> 
</s:Envelope> 
B2 KM2 Naive 3rd Agent 
B2.1 Request 
<s:Envelope xmlns:s="http://schemas.xmlsoap.org/soap/envelope/"> 
  <s:Header> 
    <To s:mustUnderstand="1" 
xmlns="http://schemas.microsoft.com/ws/2005/05/addressing/none">http://localhost:27956/SimpleEvaluation.sv
c</To> 
    <Action s:mustUnderstand="1" 
xmlns="http://schemas.microsoft.com/ws/2005/05/addressing/none">http://www.omg.org/spec/CDSS/201012/ds
sWsdl/ISimpleEvaluation/Evaluate</Action> 
  </s:Header> 
  <s:Body xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xmlns:xsd="http://www.w3.org/2001/XMLSchema"> 
    <evaluate xmlns="http://www.omg.org/spec/CDSS/201012/dss"> 
      <interactionId scopingEntityId="it.hsanmartino.cds" interactionId="0090d267d38f4d25bc8064530338b530" 
submissionTime="2017-04-07T10:05:23.3713102Z" xmlns=""></interactionId> 
      <evaluationRequest clientLanguage="it-IT" clientTimeZoneOffset="+01:00" xmlns=""> 
        <kmEvaluationRequest> 
          <kmId scopingEntityId="it.medinfo.km" businessId="NAIVEScelta3Agente" version="1.0"></kmId> 
        </kmEvaluationRequest> 
        <dataRequirementItemData> 
          <driId itemId="RequiredDataId"></driId> 
          <data> 
            <informationModelSSId scopingEntityId="org.hl7.cds" businessId="cdsinput:r2:CDSInput" 
version="2.0"></informationModelSSId> 
            <base64EncodedPayload> 
              <patient xmlns="urn:hl7-org:vmr:r2"> 
                <id root="2.16.840.1.113883.2.9.3.17.3.2.1.4" extension="00901115"></id> 
                <gender code="M" codeSystem="2.16.840.1.113883.5.1" 
codeSystemName="AdministrativeGender"></gender> 
                <birthTime value="19610711"></birthTime> 
                <age value="56" unit="years"></age> 
                <clinicalStatement xsi:type="DeniedProblem"> 
                  <id root="00901115.201704070000.4292"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <conditionCode code="4292" codeSystem="2.16.840.1.113883.6.103" codeSystemName="ICD-9-
CM"></conditionCode> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="DeniedProblem"> 
                  <id root="00901115.201704070000.33183"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <conditionCode code="33183" codeSystem="2.16.840.1.113883.6.103" codeSystemName="ICD-9-
CM"></conditionCode> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="ObservationResult"> 
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                  <id root="00901115.201704070000.20447-9"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <observationFocus code="20447-9" codeSystem="2.16.840.1.113883.6.1" 
codeSystemName="LOINC"></observationFocus> 
                  <observationValue> 
                    <value xsi:type="q1:PQ" value="33" unit="Copie/ml" xmlns:q1="urn:hl7-org:cdsdt:r2"></value> 
                  </observationValue> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="ObservationResult"> 
                  <id root="00901115.201704070000.35591-7"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <observationFocus code="35591-7" codeSystem="2.16.840.1.113883.6.1" 
codeSystemName="LOINC"></observationFocus> 
                  <observationValue> 
                    <value xsi:type="q2:PQ" value="15.1" unit="" xmlns:q2="urn:hl7-org:cdsdt:r2"></value> 
                  </observationValue> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="DeniedProblem"> 
                  <id root="00901115.201704070000.011"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <conditionCode code="011" codeSystem="2.16.840.1.113883.6.103" codeSystemName="ICD-9-
CM"></conditionCode> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="SubstanceAdministrationEvent"> 
                  <id root="00901115.201704070000.J04AB02"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <substance> 
                    <substanceCode code="J04AB02" codeSystem="2.16.840.1.113883.2.9.6.1.23" 
codeSystemName="Codice AIC Farmaco"></substanceCode> 
                  </substance> 
                  <administrationTimeInterval lowClosed="true"> 
                    <low value="00010101" xmlns="urn:hl7-org:cdsdt:r2"></low> 
                  </administrationTimeInterval> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="SubstanceAdministrationEvent"> 
                  <id root="00901115.201704070000.J05AF05"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <substance> 
                    <substanceCode code="J05AF05" codeSystem="2.16.840.1.113883.2.9.6.1.23" 
codeSystemName="Codice AIC Farmaco"></substanceCode> 
                  </substance> 
                  <administrationTimeInterval lowClosed="true"> 
                    <low value="20170407" xmlns="urn:hl7-org:cdsdt:r2"></low> 
                  </administrationTimeInterval> 
                </clinicalStatement> 
                <clinicalStatement xsi:type="SubstanceAdministrationEvent"> 
                  <id root="00901115.201704070000.J05AF06"></id> 
                  <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                  <substance> 
                    <substanceCode code="J05AF06" codeSystem="2.16.840.1.113883.2.9.6.1.23" 
codeSystemName="Codice AIC Farmaco"></substanceCode> 
                  </substance> 
                  <administrationTimeInterval lowClosed="true"> 
                    <low value="20170407" xmlns="urn:hl7-org:cdsdt:r2"></low> 
                  </administrationTimeInterval> 
                </clinicalStatement> 
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              </patient> 
            </base64EncodedPayload> 
          </data> 
        </dataRequirementItemData> 
      </evaluationRequest> 
    </evaluate> 
  </s:Body> 
</s:Envelope> 
B2.2 Response 
<s:Envelope xmlns:s="http://schemas.xmlsoap.org/soap/envelope/"> 
  <s:Header> 
    <Action s:mustUnderstand="1" 
xmlns="http://schemas.microsoft.com/ws/2005/05/addressing/none">http://www.omg.org/spec/CDSS/201012/ds
sWsdl/ISimpleEvaluation/EvaluateResponse</Action> 
  </s:Header> 
  <s:Body xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xmlns:xsd="http://www.w3.org/2001/XMLSchema"> 
    <evaluateResponse xmlns="http://www.omg.org/spec/CDSS/201012/dss"> 
      <evaluationResponse xmlns=""> 
        <finalKMEvaluationResponse> 
          <kmId scopingEntityId="it.medinfo.km" businessId="NAIVEScelta3Agente" version="1.0"></kmId> 
          <kmEvaluationResultData> 
            <evaluationResultId itemId="4e53ca45-bf97-4c09-bbc7-eddd872a72f5"></evaluationResultId> 
            <data> 
              <informationModelSSId scopingEntityId="org.hl7.cds" businessId="cdsoutput:r2:CDSOutputAsVMR" 
version="2.0"></informationModelSSId> 
              <base64EncodedPayload> 
                <templateId root="2.16.840.1.113883.3.1829.11.1.3.5" identifierName="CDSOutputAsVMR" 
xmlns="urn:hl7-org:vmr:r2"></templateId> 
                <patient xmlns="urn:hl7-org:vmr:r2"> 
                  <id root="2.16.840.1.113883.2.9.3.17.3.2.1.4" extension="00901115"></id> 
                  <gender code="M" codeSystem="2.16.840.1.113883.5.1" 
codeSystemName="AdministrativeGender"></gender> 
                  <birthTime value="19610711"></birthTime> 
                  <age value="56" unit="years"></age> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AE08J05AE03"></id> 
                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
                      <name value="Recommended"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q1="urn:hl7-org:cdsdt:r2" xsi:type="q1:INT" value="2"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <relatedEntity> 
                        <entity xsi:type="AdministrableSubstance"> 
                          <substanceCode code="J05AE03" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                        </entity> 
                      </relatedEntity> 
                      <substanceCode code="J05AE08" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                    </substance> 
                  </clinicalStatement> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AE10J05AE03"></id> 
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                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
                      <name value="Recommended"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q2="urn:hl7-org:cdsdt:r2" xsi:type="q2:INT" value="2"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <relatedEntity> 
                        <entity xsi:type="AdministrableSubstance"> 
                          <substanceCode code="J05AE03" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                        </entity> 
                      </relatedEntity> 
                      <substanceCode code="J05AE10" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                    </substance> 
                  </clinicalStatement> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AX12"></id> 
                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
                      <name value="Caution"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q3="urn:hl7-org:cdsdt:r2" xsi:type="q3:INT" value="-1"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <substanceCode code="J05AX12" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                    </substance> 
                  </clinicalStatement> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AX11"></id> 
                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
                      <name value="Avoid"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q4="urn:hl7-org:cdsdt:r2" xsi:type="q4:INT" value="-2"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <substanceCode code="J05AX11" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                    </substance> 
                  </clinicalStatement> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AX08"></id> 
                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
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                      <name value="Recommended"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q5="urn:hl7-org:cdsdt:r2" xsi:type="q5:INT" value="2"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <substanceCode code="J05AX08" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                    </substance> 
                  </clinicalStatement> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AG05"></id> 
                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
                      <name value="Recommended"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q6="urn:hl7-org:cdsdt:r2" xsi:type="q6:INT" value="2"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <substanceCode code="J05AG05" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                    </substance> 
                  </clinicalStatement> 
                  <clinicalStatement xsi:type="SubstanceAdministrationProposal"> 
                    <id root="00901115.201704070000.J05AG03"></id> 
                    <evaluatedPersonId root="2.16.840.1.113883.2.9.3.17.3.2.1.4" 
extension="00901115"></evaluatedPersonId> 
                    <attribute> 
                      <templateId root="2.16.840.1.113883.3.1829.11.14.8.7" 
identifierName="Attribute"></templateId> 
                      <name value="Acceptable alternative"></name> 
                      <value xsi:type="Value"> 
                        <value xmlns:q7="urn:hl7-org:cdsdt:r2" xsi:type="q7:INT" value="1"></value> 
                      </value> 
                    </attribute> 
                    <substance> 
                      <substanceCode code="J05AG03" codeSystem="2.16.840.1.113883.6.73" 
codeSystemName="Anatomical Therapeutic Chemical Classification System"></substanceCode> 
                    </substance> 
                  </clinicalStatement> 
                </patient> 
              </base64EncodedPayload> 
            </data> 
          </kmEvaluationResultData> 
        </finalKMEvaluationResponse> 
      </evaluationResponse> 
    </evaluateResponse> 
  </s:Body> 
</s:Envelope> 
 
 
